<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006601.pub4" GROUP_ID="SYMPT" ID="255305021509504832" MERGED_FROM="" MODIFIED="2016-06-10 13:17:16 +0100" MODIFIED_BY="Anna Erskine" REVIEW_NO="99" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2016-06-10 13:17:12 +0100" MODIFIED_BY="Anna Erskine">
<TITLE>Codeine, alone and with paracetamol (acetaminophen), for cancer pain</TITLE>
<CONTACT MODIFIED="2016-06-10 13:17:12 +0100" MODIFIED_BY="Anna Erskine"><PERSON ID="483765A782E26AA2016509FE486B841E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sebastian</FIRST_NAME><LAST_NAME>Straube</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>straube@ualberta.ca</EMAIL_1><EMAIL_2>sebastian.straube@googlemail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Medicine, Division of Preventive Medicine</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>5-30F University Terrace</ADDRESS_1><ADDRESS_2>8303-112 Street</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2T4</ZIP><REGION>AB</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>780-492-6291</PHONE_1><FAX_1>780-492-9677</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-06-10 13:17:12 +0100" MODIFIED_BY="Anna Erskine"><PERSON ID="87985891959246942567120918135641" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carmen</FIRST_NAME><LAST_NAME>Straube</LAST_NAME><EMAIL_1>carmen.schremmer@med.uni-goettingen.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Haematology and Oncology</DEPARTMENT><ORGANISATION>University Medical Center Göttingen</ORGANISATION><ADDRESS_1>Robert-Koch-Straße 40</ADDRESS_1><CITY>Göttingen</CITY><ZIP>37075</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="5475F46C82E26AA20187B79619319C6E" ROLE="AUTHOR"><FIRST_NAME>Sheena</FIRST_NAME><LAST_NAME>Derry</LAST_NAME><POSITION>Senior Research Officer</POSITION><EMAIL_1>sheena.derry@ndcn.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Pain Research Unit</ADDRESS_1><ADDRESS_2>Churchill Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 7LE</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 225405</PHONE_1><FAX_1>+44 1865 225402</FAX_1></ADDRESS></PERSON><PERSON ID="15643" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kenneth</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Jackson</LAST_NAME><SUFFIX>II, PharmD., CPE</SUFFIX><POSITION>Professor &amp; Chair</POSITION><EMAIL_1>kjackson@ularkin.org</EMAIL_1><EMAIL_2>kenneth.c.jackson.2@gmail.com</EMAIL_2><MOBILE_PHONE>+1 503 840 4098</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Clinical and Administrative Sciences, College of Pharmacy</DEPARTMENT><ORGANISATION>Larkin Health Sciences Institute</ORGANISATION><ADDRESS_1>18301 N. Miami Avenue Suite 1</ADDRESS_1><CITY>Miami</CITY><ZIP>33169</ZIP><REGION>FL</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+ 1 305.760.7500</PHONE_1><FAX_1>+ 1 305.284.7787</FAX_1></ADDRESS></PERSON><PERSON ID="10441" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Philip</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Wiffen</LAST_NAME><POSITION>Editor</POSITION><EMAIL_1>phil.wiffen@ndcn.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics)</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Pain Research Unit</ADDRESS_1><ADDRESS_2>Churchill Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 7LE</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 01865225674</PHONE_1></ADDRESS></PERSON><PERSON ID="15599" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rae</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Bell</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>rae.bell@helse-bergen.no</EMAIL_1><EMAIL_2>raeb@frisurf.no</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Pain Management and Palliative Care &amp; Regional Centre for Excellence in Palliative Care</DEPARTMENT><ORGANISATION>Haukeland University Hospital</ORGANISATION><CITY>Bergen</CITY><ZIP>N-5021</ZIP><COUNTRY CODE="NO">Norway</COUNTRY><PHONE_1>+47 55 97 4012</PHONE_1><FAX_1>+47 55 97 4010</FAX_1></ADDRESS></PERSON><PERSON ID="1E4765BA82E26AA2009C393DE2095699" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Scott</FIRST_NAME><LAST_NAME>Strassels</LAST_NAME><SUFFIX>PharmD, PhD</SUFFIX><EMAIL_1>scotts1@uw.edu</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>8002 Davis Dr</ADDRESS_1><CITY>Clayton</CITY><ZIP>63105</ZIP><REGION>MO</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>(512) 944-5231</PHONE_1></ADDRESS></PERSON><PERSON ID="483765A782E26AA2016509FE486B841E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sebastian</FIRST_NAME><LAST_NAME>Straube</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>straube@ualberta.ca</EMAIL_1><EMAIL_2>sebastian.straube@googlemail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Medicine, Division of Preventive Medicine</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>5-30F University Terrace</ADDRESS_1><ADDRESS_2>8303-112 Street</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2T4</ZIP><REGION>AB</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>780-492-6291</PHONE_1><FAX_1>780-492-9677</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-07-25 10:03:16 +0100" MODIFIED_BY="Anna Hobson">
<UP_TO_DATE>
<DATE DAY="5" MONTH="3" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="3" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="9" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="9" YEAR="2014"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2016-06-02 10:13:05 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2016-06-02 10:13:05 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="2" MONTH="6" YEAR="2016"/>
<DESCRIPTION>
<P>See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-03-28 10:11:38 +0000" MODIFIED_BY="Jessica Thomas">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-03-28 10:11:38 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="6" MONTH="2" YEAR="2013"/>
<DESCRIPTION>
<P>This is an update of a previous version of this protocol that had been written by Kenneth C Jackson and Philip J Wiffen. In this updated version, Carmen Schremmer, Sheena Derry, Rae F Bell, Scott Strassels, and Sebastian Straube have joined the original authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-11-19 09:05:33 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>The protocol has been reactivated and is currently being updated. Carmen Schremmer, Sheena Derry, Rae F Bell, Scott Strassels, and Sebastian Straube have joined the authors of the previous protocol, Kenneth C Jackson and Philip J Wiffen.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-11-19 09:05:14 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Authors have made no progress with this protocol in five years. Therefore new authors are being sought to take over this protocol.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-06-08 11:04:28 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-09 17:53:23 +0000" MODIFIED_BY="Jessica Thomas">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-10-08 14:30:59 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-10-08 14:30:59 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-10-08 14:30:59 +0100" MODIFIED_BY="[Empty name]">
<NAME>Oxford Pain Relief Trust</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-06-02 10:13:11 +0100" MODIFIED_BY="Anna Erskine">
<SUMMARY MODIFIED="2014-07-25 10:04:46 +0100" MODIFIED_BY="Heather Maxwell">
<TITLE MODIFIED="2014-02-12 14:55:26 +0000" MODIFIED_BY="[Empty name]">Codeine, alone and with paracetamol (acetaminophen), for cancer pain</TITLE>
<SUMMARY_BODY MODIFIED="2014-07-25 10:04:46 +0100" MODIFIED_BY="Heather Maxwell">
<P>Codeine is an opioid medication commonly used worldwide to treat pain including cancer pain. Oral codeine, either alone or in combination with paracetamol, provided good pain relief for some people with cancer pain, based on limited amounts of information.</P>
<P>In this review we set out to estimate how well codeine worked, how many people had side effects, and how severe those side effects were - for example, whether they were so severe that participants stopped taking their oral codeine. We included 15 studies with 721 participants. The studies we found had methodological shortcomings: they were small and of short duration. They also reported results in different ways, so that it was not possible to combine results. In seven of the eight studies that compared codeine with placebo, codeine was better than placebo. In studies that compared codeine with another drug, the results were similar. Codeine at doses of 30 mg to 120 mg, alone or in combination with paracetamol, does seem to provide a good level of pain relief for some people with cancer pain. We cannot be certain about how many people will get this benefit, and we do not know whether, or by how much, adding paracetamol increases its effect. Codeine increases nausea, vomiting, and constipation, and may cause drowsiness or dizziness if used for more than a week. Some people will stop taking codeine because of the side effects.</P>
<P>More trials comparing codeine with other treatments and using patient-centred outcomes are needed. The role of codeine in mild cancer pain, in addition to moderate to severe cancer pain, should be investigated.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-07-25 10:04:34 +0100" MODIFIED_BY="Heather Maxwell">
<ABS_BACKGROUND MODIFIED="2014-07-25 10:03:33 +0100" MODIFIED_BY="Heather Maxwell">
<P>Pain is very common in patients with cancer. Opioid analgesics, including codeine, play a significant role in major guidelines on the management of cancer pain, particularly for mild to moderate pain. Codeine is widely available and inexpensive, which may make it a good choice, especially in low-resource settings. Its use is controversial, in part because codeine is not effective in a minority of patients who cannot convert it to its active metabolite (morphine), and also because of concerns about potential abuse, and safety in children.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-03-05 11:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy and safety of codeine used alone or in combination with paracetamol for relieving cancer pain.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-04-24 16:53:12 +0100" MODIFIED_BY="Anna Hobson">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; <I>The Cochrane Library</I> 2014, Issue 2), MEDLINE and EMBASE from inception to 5 March 2014, supplemented by searches of clinical trial registries and screening of the reference lists of the identified studies and reviews in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-07-25 10:04:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>We sought randomised, double-blind, controlled trials using single or multiple doses of codeine, with or without paracetamol, for the treatment of cancer pain. Trials could have either parallel or cross-over design, with at least 10 participants per treatment group. Studies in children or adults reporting on any type, grade, and stage of cancer were eligible. We accepted any formulation, dosage regimen, and route of administration of codeine, and both placebo and active controls.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-07-25 10:04:23 +0100" MODIFIED_BY="Heather Maxwell">
<P>Two review authors independently read the titles and abstracts of all studies identified by the searches and excluded those that clearly did not meet the inclusion criteria. For the remaining studies, two authors read the full manuscripts and assessed them for inclusion. We resolved discrepancies between review authors by discussion. Included studies were described qualitatively, since no meta-analysis was possible because of the small amount of data identified, and clinical and methodological between-study heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-07-25 10:04:34 +0100" MODIFIED_BY="Heather Maxwell">
<P>We included 15 studies including 721 participants with cancer pain due to diverse types of malignancy. All studies were performed on adults; there were no studies on children. The included studies were of adequate methodological quality, but all except for one were judged to be at a high risk of bias because of small study size, and six because of methods used to deal with missing data or high withdrawal rates. Three studies used a parallel group design; the remainder were cross-over trials in which there was an adequate washout period, but only one reported results for treatment periods separately.</P>
<P>Twelve studies used codeine as a single agent and three combined it with paracetamol. Ten studies included a placebo arm, and 14 included one or more of 16 different active drug comparators or compared different routes of administration. Most studies investigated the effect of a single dose of medication, while five used treatment periods of one, seven or 21 days. Most studies used codeine at doses of 30 mg to 120 mg.</P>
<P>There were insufficient data for any pooled analysis. Only two studies reported our preferred responder outcome of 'participants with at least 50% reduction in pain' and two reported 'participants with no worse than mild pain'. Eleven studies reported treatment group mean measures of pain intensity or pain relief; overall for these outcome measures, codeine or codeine plus paracetamol was numerically superior to placebo and equivalent to the active comparators.</P>
<P>Adverse event reporting was poor: only two studies reported the number of participants with any adverse event specified by treatment group and only one reported the number of participants with any serious adverse event. In multiple-dose studies nausea, vomiting and constipation were common, with somnolence and dizziness frequent in the 21-day study. Withdrawal from the studies, where reported, was less than 10% except in two studies. There were three deaths, in all cases due to the underlying cancer.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-06-02 15:27:00 +0100" MODIFIED_BY="[Empty name]">
<P>We identified only a small amount of data in studies that were both randomised and double-blind. Studies were small, of short duration, and most had significant shortcomings in reporting. The available evidence indicates that codeine is more effective against cancer pain than placebo, but with increased risk of nausea, vomiting, and constipation. Uncertainty remains as to the magnitude and time-course of the analgesic effect and the safety and tolerability in longer-term use. There were no data for children.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-07-25 10:09:32 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-07-25 10:05:07 +0100" MODIFIED_BY="Heather Maxwell">
<CONDITION MODIFIED="2014-06-27 13:51:40 +0100" MODIFIED_BY="Anna Hobson">
<P>Pain is very common in patients with a diagnosis of cancer, and for many it is the most disruptive and distressing symptom. It may be due to the primary cancer itself or metastases, or to treatment (for example chemotherapy, radiation, surgery) or to a comorbid condition. A systematic review of pain prevalence in patients with cancer reported rates in excess of 50% (52% to 70%) for six different cancers. More than one third reported pain of moderate to severe intensity (<LINK REF="REF-van-den-Beuken_x002d_van-Everdingen-2007" TYPE="REFERENCE">van den Beuken-van Everdingen 2007</LINK>). For the purposes of this review, cancer pain is defined broadly as pain of unspecified origin in any patient with cancer or a history of cancer.</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-07-25 10:05:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>Codeine is an opioid analgesic, and is the most widely used, naturally occurring narcotic in medical treatment in the world (<LINK REF="REF-Opiates-2013" TYPE="REFERENCE">Opiates 2013</LINK>). Codeine can also be synthesised from morphine. It is most commonly administered by mouth (as tablets or syrup), but is also available for intramuscular and subcutaneous injections, and in some countries as suppositories. In many countries it is a controlled substance, but it may still be available in small quantities without prescription, in combination analgesics with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) and in cough syrups. In 2012 in England, there were almost 3.6 million prescriptions in primary care for codeine phosphate, mostly as 30 mg and 15 mg tablets, with many more for combination products (<LINK REF="REF-PCA-2013" TYPE="REFERENCE">PCA 2013</LINK>). The <LINK REF="REF-BNF-2014" TYPE="REFERENCE">BNF 2014</LINK> suggests a dose of 30 mg to 60 mg every four hours as required for mild to moderate pain in adults. These doses are usually available on prescription only.</P>
<P>Codeine is used for a variety of painful states and conditions, including pain associated with cancer. Opioid analgesics, including codeine, play a significant role in major guidelines associated with the management of pain for patients diagnosed with cancer (<LINK REF="REF-Caraceni-2012" TYPE="REFERENCE">Caraceni 2012</LINK>; <LINK REF="REF-Jacox-1994" TYPE="REFERENCE">Jacox 1994</LINK>; <LINK REF="REF-Miaskowski-2005" TYPE="REFERENCE">Miaskowski 2005</LINK>; <LINK REF="REF-Ripamonti-2012-I" TYPE="REFERENCE">Ripamonti 2012 I</LINK>; <LINK REF="REF-SIGN-2008" TYPE="REFERENCE">SIGN 2008</LINK>; <LINK REF="REF-WHO-1996" TYPE="REFERENCE">WHO 1996</LINK>). In the context of these guidelines, codeine is considered an analgesic for moderate pain or for situations where simple analgesics (for example NSAIDs or paracetamol) alone are ineffective or provide suboptimal analgesia. Codeine has been used in children, although recent guidance is critical of this use (<LINK REF="REF-RCPCH-2013" TYPE="REFERENCE">RCPCH 2013</LINK>; <LINK REF="REF-WHO-2012" TYPE="REFERENCE">WHO 2012</LINK>).</P>
<P>In some clinical guidelines, codeine is referred to as a 'weak' opioid analgesic. Codeine and tramadol are defined as step II opioids on the WHO analgesic ladder. The role and utility of step II opioids in cancer pain are controversial (<LINK REF="REF-Ripamonti-2012-II" TYPE="REFERENCE">Ripamonti 2012 II</LINK>) and there is currently a discussion as to whether step II opioids should be omitted from the ladder since low doses of step III opioids are equally, or in the case of 'poor metabolisers', more effective. The European Association for Palliative Care currently recommends both options (<LINK REF="REF-Caraceni-2012" TYPE="REFERENCE">Caraceni 2012</LINK>).</P>
<P>As with other opioid analgesics, codeine is associated with significant adverse effects. In acute dosing situations, concerns centre around respiratory depression and other adverse effects mediated by the central nervous system, such as excessive sedation or nausea and vomiting. The principal adverse effect associated with chronic dosing is constipation, which in most patients requires prophylactic use of stimulant laxatives (<LINK REF="REF-Jackson-2001" TYPE="REFERENCE">Jackson 2001</LINK>). The use of codeine for postoperative pain in children is currently under serious debate due to safety issues (<LINK REF="REF-Kuehn-2013" TYPE="REFERENCE">Kuehn 2013</LINK>). As an opioid, codeine is a drug with the potential for abuse and addiction.</P>
<P>Codeine use in cancer pain remains consistent and in some settings may be increasing (<LINK REF="REF-De-Conno-2003" TYPE="REFERENCE">De Conno 2003</LINK>). This may be due to earlier treatment of cancer pain, codeine becoming more widely available, prescribing preferences, or other issues, such as cost. Codeine use is primarily promoted for cases of mild to moderate pain, or when simple analgesics in isolation are inadequate (<LINK REF="REF-Jadad-1995" TYPE="REFERENCE">Jadad 1995</LINK>). The role of codeine in more severe pain is not well described. Opioid use in more severe pain may be limited by the development of constipation, which may be even more problematic for codeine than other opioids (<LINK REF="REF-Bennett-2003" TYPE="REFERENCE">Bennett 2003</LINK>; <LINK REF="REF-Jackson-2001" TYPE="REFERENCE">Jackson 2001</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-07-25 10:05:07 +0100" MODIFIED_BY="Heather Maxwell">
<P>Codeine is a prodrug. It is metabolised to morphine in the liver. The analgesic effect of morphine is due to its action on the mu opioid receptor. Morphine is metabolised in the liver and brain, the predominant metabolites being morphine-3-glucuronide and morphine-6-glucuronide. The total production of morphine-3-glucuronide is approximately five times higher than that of morphine-6-glucuronide. Morphine-3-glucuronide has low potency at the mu receptor and is considered to be inactive in humans, while morphine-6-glucuronide is a mu receptor agonist with analgesic effect and is more potent than morphine (<LINK REF="REF-Paul-1989" TYPE="REFERENCE">Paul 1989</LINK>; <LINK REF="REF-Wittwer-2006" TYPE="REFERENCE">Wittwer 2006</LINK>).</P>
<P>In most people 5% to 10% of codeine is converted to morphine; a 30 mg dose of codeine is considered equivalent to a 3 mg dose of morphine. The ability to metabolise codeine varies between individuals. Some (up to 10% of Caucasians, 2% of Asians, and 1% of Arabs) are 'poor metabolisers' (<LINK REF="REF-Cascarbi-2003" TYPE="REFERENCE">Cascarbi 2003</LINK>) with low rates of conversion, and in these people codeine is a relatively ineffective analgesic. At the other extreme, a few individuals are 'extensive metabolisers' with high rates of conversion, and this puts them at increased risk of toxicity from standard doses. There are rare case reports of deaths attributed to ultrarapid metabolism of codeine administered at recommended doses (<LINK REF="REF-Ciszkowski-2009" TYPE="REFERENCE">Ciszkowski 2009</LINK>; <LINK REF="REF-Madadi-2007" TYPE="REFERENCE">Madadi 2007</LINK>).</P>
<P>A number of medications can interfere with the enzymes that catalyse the metabolism of codeine, and by increasing or decreasing the extent of conversion they can change the analgesic effect. The selective serotonin reuptake inhibitors fluoxetine and paroxetine (used for the treatment of depression which may present as a co-morbidity along with malignant disease) as well as the serotonin and noradrenaline reuptake inhibitor duloxetine (which may be used for pain management) for example, reduce conversion, and other drugs, such as rifampicin and dexamethasone, increase it.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-07-23 16:18:16 +0100" MODIFIED_BY="Heather Maxwell">
<P>There is clearly an unmet need for pain control amongst cancer patients. Codeine is inexpensive and has a long track record. However, there is an ongoing controversy as to whether there is a place for step II opioids in the treatment of cancer pain.</P>
<P>A systematic review is needed to inform clinical practice and guideline development. This Cochrane review will investigate how effective codeine is in controlling cancer pain compared to placebo or other analgesics, and whether adding paracetamol to codeine confers any benefit.</P>
<P>The present review is one of a series of reviews whose aim is to evaluate the place of opioid analgesics in the management of cancer pain. Other important reviews include updates of oral morphine for cancer pain (<LINK REF="REF-Wiffen-2013" TYPE="REFERENCE">Wiffen 2013</LINK>), transdermal fentanyl for cancer pain (<LINK REF="REF-Hadley-2013" TYPE="REFERENCE">Hadley 2013</LINK>), and methadone for cancer pain (<LINK REF="REF-Nicholson-2007" TYPE="REFERENCE">Nicholson 2007</LINK>), which is currently being updated. Other relevant Cochrane reviews include NSAIDs or paracetamol, alone or combined with opioids, for cancer pain (<LINK REF="REF-McNicol-2005" TYPE="REFERENCE">McNicol 2005</LINK>), single dose oral codeine, as a single agent, for acute postoperative pain in adults (<LINK REF="REF-Derry-2010" TYPE="REFERENCE">Derry 2010</LINK>), and single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults (<LINK REF="REF-Toms-2009" TYPE="REFERENCE">Toms 2009</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-06-02 15:27:14 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy and safety of codeine used alone or in combination with paracetamol for relieving cancer pain when compared with placebo or an alternative active treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-07-25 10:05:50 +0100" MODIFIED_BY="Heather Maxwell">
<SELECTION_CRITERIA MODIFIED="2014-07-25 10:05:13 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2014-07-25 10:05:13 +0100" MODIFIED_BY="Heather Maxwell">
<P>We sought randomised, double-blind, placebo- or active-controlled studies using single or multiple doses of codeine, with or without paracetamol, for the treatment of cancer pain. Studies could use either a parallel or cross-over design and had to have at least 10 participants per treatment group. Studies including participants with pain of different (cancer and non-cancer) aetiologies were eligible for inclusion if they reported results separately for participants with cancer pain or where the majority of participants had cancer pain. We included studies reported as full journal publications. We would have also included trials with information available in the form of substantial clinical trial summaries. We did not include studies published only as short abstracts (typically conference abstracts).<I>
<BR/>
</I>
</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Studies had to report on children or adults with cancer pain. We accepted any type, grade, and stage of cancer. In order to be inclusive, we accepted studies conducted in populations with cancer and non-cancer pain, as long as the majority of patients had cancer; we would have excluded them in a sensitivity analysis if they had contributed to any pooled analysis. Studies where only a minority of patients had cancer pain and where results were not reported separately for such patients were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-02-28 12:25:13 +0000" MODIFIED_BY="[Empty name]">
<P>Studies had to investigate codeine, alone or in combination with paracetamol, using any formulation, dosage regimen, and route of administration. Comparators were placebo or an alternative active treatment. <I>
<BR/>
</I>
</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Our preferred outcome measures are based on recent guidance as provided by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>), the Special Interest Group on Systematic Reviews in Pain Relief of the International Association for the Study of Pain, and the Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors (<LINK REF="REF-Moore-2010" TYPE="REFERENCE">Moore 2010</LINK>). We preferred responder outcomes over treatment group average outcomes; the former are more informative than the latter as there is considerable between-participant heterogeneity with regard to pain intensity and pain relief in clinical trials (<LINK REF="REF-Moore-2013" TYPE="REFERENCE">Moore 2013</LINK>).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-04-09 14:19:09 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Participants with at least 50% reduction in pain (preferred outcome)</LI>
<LI>Participants with pain intensity below 30/100 mm on the visual analogue scale (VAS) or 3/10 on the numeric rating scale (NRS) (preferred outcome)</LI>
<LI>Patient Global Impression of Change (participants who are much or very much improved)</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-03-03 15:19:50 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Treatment group average pain intensity or pain relief</LI>
<LI>Functioning (any scale)</LI>
<LI>Adverse events: any adverse events, serious adverse events</LI>
<LI>Withdrawals: any withdrawals, lack of efficacy withdrawals, adverse event withdrawals</LI>
<LI>Death</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-04-16 16:24:54 +0100" MODIFIED_BY="Anna Hobson">
<ELECTRONIC_SEARCHES MODIFIED="2014-03-05 15:18:20 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the following databases:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), <I>The Cochrane Library,</I> Issue 2 of 12, 2014;</LI>
<LI>MEDLINE (via PubMed) from inception to 5 March 2014;</LI>
<LI>EMBASE (via Ovid) from inception to 5 March 2014.</LI>
</UL>
<P>We developed detailed search strategies for each database searched, based on the strategy developed for MEDLINE and revised appropriately for each database. <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> details the MEDLINE search strategy, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> the CENTRAL search strategy and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> the EMBASE search strategy.</P>
<P>We applied no language restrictions.<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-04-16 16:24:54 +0100" MODIFIED_BY="Anna Hobson">
<P>We screened the bibliographies of studies and review articles in this field for other potentially relevant studies. We also searched trials registries for details of unpublished and ongoing trials: the metaRegister of controlled trials (mRCT) (<A HREF="http://www.controlled-trials.com/mrct">www.controlled-trials.com/mrct</A>), <A HREF="http://clinicaltrials.gov/">clinicaltrials.gov</A>, and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>). The search was performed on 5 March 2014.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-07-25 10:05:50 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY_SELECTION MODIFIED="2014-04-11 14:48:44 +0100" MODIFIED_BY="Anna Hobson">
<P>Two review authors independently read the titles and abstracts of all studies identified by the searches and excluded those that clearly did not meet the inclusion criteria. For the remaining studies two authors read the full manuscripts to assess if they should be included. We resolved discrepancies between review authors by discussion. We did not anonymise studies before selection. Reasons for excluding studies are reported, unless the studies were excluded on the basis of title or abstract.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-04-11 14:31:44 +0100" MODIFIED_BY="Anna Hobson">
<P>Two review authors independently extracted data using a standard form. Discrepancies were resolved by discussion before data entry into Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). Data extracted included:</P>
<OL>
<LI>publication details;</LI>
<LI>patient population, number of patients, age, type of cancer;</LI>
<LI>study design and duration;</LI>
<LI>description of the pharmacological intervention;</LI>
<LI>description of the instruments used to evaluate pain;</LI>
<LI>outcome measures as detailed above;</LI>
<LI>quality score as described below.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-07-25 10:05:21 +0100" MODIFIED_BY="Heather Maxwell">
<P>We assessed methodological study quality using a validated scoring system, the Oxford Quality Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). For inclusion, trials needed to score at least two points on this scale (out of a possible five points), one for randomisation and one for blinding.</P>
<P>We also used the &#8216;Risk of bias&#8217; tool available in RevMan 5, using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and adapted from those used by the Pregnancy and Childbirth Group, with any disagreements resolved by discussion. The following were assessed for each study.</P>
<OL>
<LI>Random sequence generation (checking for possible selection bias). The method used to generate the allocation sequence was assessed as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non-random process (e.g. odd or even date of birth; hospital or clinic record number).</LI>
<LI>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions was assessed as to whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. The methods were assessed as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (e.g. open list).</LI>
<LI>Blinding of outcome assessment (checking for possible detection bias). The methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received were assessed as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding e.g. identical tablets; matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved). We excluded studies that were not double-blind.</LI>
<LI>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). The methods used to deal with incomplete data were assessed as: low risk (&lt; 10% of participants did not complete the study or a &#8216;baseline observation carried forward&#8217; analysis was used); unclear risk of bias ('last observation carried forward' analysis was used); high risk of bias ('completer' analysis was used).</LI>
<LI>Size of study (checking for possible biases confounded by small size). Studies were assessed as being at low risk of bias (&#8805; 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm).</LI>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-07-25 10:05:27 +0100" MODIFIED_BY="Heather Maxwell">
<P>We planned to use dichotomous data to calculate risk ratios (RR) with 95% confidence intervals (CI), and would have calculated numbers needed to treat to benefit (NNT) as the reciprocal of the absolute risk reduction (<LINK REF="REF-McQuay-1998" TYPE="REFERENCE">McQuay 1998</LINK>). For unwanted effects, the NNT becomes the number needed to treat to harm (NNH), and would have been calculated in the same manner.</P>
<P>We would have used the following terms to describe adverse outcomes in terms of harm, or prevention of harm.</P>
<UL>
<LI>When significantly fewer adverse outcomes occur with codeine than with control (placebo), we would have used the term number needed to treat to prevent one event (NNTp).</LI>
<LI>When significantly more adverse outcomes occur with codeine compared with control (placebo) we would have used the term number needed to harm or cause one event (NNH).</LI>
</UL>
<P>If appropriate, we would have used continuous data to calculate the mean difference (± standard deviation (SD)) between treatment groups.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2014-06-02 15:40:35 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to use intention-to-treat (ITT) analysis: patients who were randomised, took the study medication, and gave a minimum of one post-baseline assessment. Where there were missing participants or information, these were assigned to a zero improvement category where possible. The method of dealing with data from withdrawals was ascertained where possible. In original studies, participants who withdrew may have been analysed using last observation carried forward (that is their level of pain when stopping the medication) or returned to their baseline observation.</P>
<P>We report when there are substantial numbers (&gt; 10%) of participants missing from the analyses. There were insufficient data to conduct meta-analyses. Had meta-analyses been conducted, we would have performed sensitivity analyses to assess the impact of including studies with substantial numbers (&gt; 10%) of participants missing from the analyses reported in the studies.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Had meta-analyses been conducted, heterogeneity would have been assessed using L'Abbé plots, a visual method for assessing differences in results of individual studies (<LINK REF="REF-L_x0027_Abb_x00e9_-1987" TYPE="REFERENCE">L'Abbé 1987</LINK>), and with the I<SUP>2 </SUP>statistic. There could have been effects of differences between patients, environments (inpatient versus outpatient), and outcome measures. These would have been explored with subgroup and sensitivity analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-01-24 13:28:25 +0000" MODIFIED_BY="[Empty name]">
<P>The aim of this review was to use dichotomous data of known utility (<LINK REF="REF-Moore-2010" TYPE="REFERENCE">Moore 2010</LINK>). The review does not depend on what authors of the original studies chose to report or not.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-07-25 10:05:38 +0100" MODIFIED_BY="Heather Maxwell">
<P>There were insufficient data to conduct meta-analyses; to pool data we would have required at least two studies and 200 participants for the outcome and comparison in question (<LINK REF="REF-Moore-1998" TYPE="REFERENCE">Moore 1998</LINK>). If data had been available we would have performed data analysis using RevMan 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>), and we planned to carry out separate analyses for codeine used alone and codeine with paracetamol.</P>
<P>For dichotomous outcomes, we would have calculated the RR of benefit or harm with 95% CI using a fixed-effect model (<LINK REF="REF-Morris-1995" TYPE="REFERENCE">Morris 1995</LINK>); NNT or NNH would have been calculated using the pooled number of events by the method of Cook and Sackett (<LINK REF="REF-Cook-1995" TYPE="REFERENCE">Cook 1995</LINK>).</P>
<P>For continuous outcomes (for example, group mean data for pain intensity or pain relief), we would have calculated the mean difference between the treatment groups. It was planned to meta-analyse the treatment group mean data only when the studies were similar enough to allow pooling and when the underlying individual data were normally distributed. We would have used fixed-effect model meta-analysis unless there was evidence of heterogeneity, when we would have used the random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-07-25 10:05:46 +0100" MODIFIED_BY="Heather Maxwell">
<P>We planned to carry out the following subgroup analyses, had they been appropriate.</P>
<UL>
<LI>Immediate release codeine versus modified release codeine.</LI>
<LI>Single dose versus multiple dose.</LI>
<LI>By type of cancer.</LI>
<LI>By age.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-07-25 10:05:50 +0100" MODIFIED_BY="Heather Maxwell">
<P>We planned to carry out the following sensitivity analyses, had they been appropriate.</P>
<UL>
<LI>Studies including participants with cancer pain only versus studies including participants with cancer and other types of pain.</LI>
<LI>Studies with an Oxford Quality Score &#8805; 3 versus those with an Oxford Quality Score of 2.</LI>
<LI>Studies using an enriched enrolment design versus studies using non-enriched enrolment (<LINK REF="REF-Straube-2008" TYPE="REFERENCE">Straube 2008</LINK>).</LI>
</UL>
<P>No sensitivity analyses were performed.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-07-25 10:09:16 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-07-25 10:06:23 +0100" MODIFIED_BY="Heather Maxwell">
<SEARCH_RESULTS MODIFIED="2014-07-25 10:05:54 +0100" MODIFIED_BY="Heather Maxwell">
<P>Electronic searches identified the following numbers of reports: MEDLINE: 112, EMBASE: 469, CENTRAL: 105. Screening reference lists identified five reports. Searching trial registries retrieved no additional relevant studies. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-07-25 10:06:19 +0100" MODIFIED_BY="Heather Maxwell">
<P>We included 15 studies (<LINK REF="STD-Beaver-1978-I" TYPE="STUDY">Beaver 1978 I</LINK>; <LINK REF="STD-Beaver-1978-II" TYPE="STUDY">Beaver 1978 II</LINK>; <LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>; <LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>; <LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>; <LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>; <LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>; <LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK>; <LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>; <LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK>; <LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>; <LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>; <LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>; <LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>; <LINK REF="STD-Staquet-1993" TYPE="STUDY">Staquet 1993</LINK>) with a total of 721 participants with cancer pain due to diverse types of malignancy. One study (<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>) claimed to involve participants "in pain from cancer" but included one participant with Paget's disease. Another study (<LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>) enrolled adults with chronic pathologic pain, most of whom had various types of cancer. Although neither study reported results separately for cancer participants, we decided to include these studies, intending to exclude them in a sensitivity analysis if they contributed to any pooled analysis, which they did not.</P>
<P>All studies were performed in adults; there were no studies in children. The mean age of the participants, where specified, varied between 51 and 64 years. The sex of the participants was not always stated; in the studies that reported it, the numbers were similar and overall were balanced (278 women, 268 men). One study included only women (<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>). Baseline pain intensity was at least moderate (&#8805; 40/100 mm) in all studies except <LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>, where it was not reported but likely to be mild, since the placebo group had pain intensities of 33/100 to 38/100 from days one to seven.</P>
<P>Three studies investigated codeine together with paracetamol (<LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>; <LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK>; <LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>); all others investigated codeine as a single agent. Ten studies included a placebo arm (<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>; <LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>; <LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>; <LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>; <LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>; <LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK>; <LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>; <LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>; <LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>; <LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>). Oral codeine was compared with intramuscular codeine (<LINK REF="STD-Beaver-1978-I" TYPE="STUDY">Beaver 1978 I</LINK>), and intramuscular codeine with intramuscular oxycodone and morphine (<LINK REF="STD-Beaver-1978-II" TYPE="STUDY">Beaver 1978 II</LINK>), at various doses. Other active comparators for oral codeine were an investigational drug (Z 424) (<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>), ketorolac tromethamine (<LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>), codeine plus ibuprofen (<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>), benzopyranoperidine (<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>), aspirin (<LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK>), tetrahydrocannabinol (TCH) (<LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>), ciramadol (<LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>), alclofenac (<LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>), a synthetic nitrogen analogue of tetrahydrocannabinol (NIB) (<LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>), as well as piroxicam and piroxicam plus codeine (<LINK REF="STD-Staquet-1993" TYPE="STUDY">Staquet 1993</LINK>). Codeine plus paracetamol was compared with hydrocodone plus paracetamol (<LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>), tramadol plus paracetamol (<LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK>), and tramadol alone (<LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>).</P>
<P>In single-dose studies, the dose of codeine used was usually 30 mg to 180 mg (360 mg in a comparison with intramuscular opioids). In the study with one-day treatment periods, the doses of codeine were 30 mg and 60 mg. In studies with seven-day treatment periods, the dose of codeine was 100 mg to 200 mg (controlled release) every two hours, and up to 320 mg daily (mean 200 mg), while doses for the combination of codeine plus paracetamol were 240 mg plus 2400 mg, and up to 300 mg plus 5000 mg daily.</P>
<P>Three studies used a parallel group design (<LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>; <LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>; <LINK REF="STD-Staquet-1993" TYPE="STUDY">Staquet 1993</LINK>) and the other 12 used a cross-over design. Most studies investigated the effect of a single dose of medication, usually over a period of six hours (<LINK REF="STD-Beaver-1978-I" TYPE="STUDY">Beaver 1978 I</LINK>; <LINK REF="STD-Beaver-1978-II" TYPE="STUDY">Beaver 1978 II</LINK>; <LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>; <LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>; <LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK>; <LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>; <LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>; <LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>; <LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>; <LINK REF="STD-Staquet-1993" TYPE="STUDY">Staquet 1993</LINK>). The other five studies used treatment periods of one day (<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>), seven days (<LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>; <LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>; <LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK>) or 21 days (<LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>) for each intervention. Washout for cross-over studies was considered to be adequate.</P>
<P>See the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for details.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-07-25 10:06:23 +0100" MODIFIED_BY="Heather Maxwell">
<P>Fourteen studies were examined as full texts and excluded, most often because they investigated mixed populations with only a minority of participants having cancer, because they did not include a codeine or codeine plus paracetamol treatment arm, or because they were not randomised and double-blind. One study had fewer than 10 participants per treatment arm. See the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table for details. Other articles identified by the searches were excluded on the basis of their titles and abstracts without needing to obtain the full texts.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-25 10:06:33 +0100" MODIFIED_BY="Heather Maxwell">
<P>Most of the included studies achieved total scores of three to five on the five-point Oxford Quality Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>); two had scores of only two (<LINK REF="STD-Beaver-1978-II" TYPE="STUDY">Beaver 1978 II</LINK>; <LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>). Points were lost because of inadequate descriptions of the method of randomisation (13 studies), not describing withdrawals (four studies) and not describing the method of double-blinding (four studies).</P>
<P>The 'Risk of bias' assessment (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) shows that all except one (<LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>) of the included studies were at a high risk of bias because of small study size. Blinding of outcome assessment was largely adequate. Failure to provide details of the method used to generate the random number sequence or the method of allocation concealment is likely to reflect the age of the studies and does not necessarily indicate inadequate methods. Six studies were judged to be at high risk of bias because of imputation or withdrawal rates of &gt;10%. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-07-25 10:09:16 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Efficacy</HEADING>
<P>Because of methodological between-study heterogeneity (participant characteristics, interventions, study design, outcomes assessed) and small numbers of participants, no meaningful pooling of results could be undertaken. Details of the results of individual studies are tabulated in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> (efficacy), <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> (adverse events and withdrawals), and <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> (specific adverse events in multiple-dose studies).</P>
<P>To avoid repetition throughout the review, we have specified the route of administration only where codeine has not been administered orally.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Codeine and codeine plus paracetamol versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Participants with at least 50% reduction in pain</HEADING>
<P>Only two small studies reported this outcome. Both gave single doses of study medication and reported results over six hours.</P>
<P>
<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK> reported that 17/35 participants (49%) experienced at least a 50% reduction in pain intensity with codeine 60 mg, 20/35 (57%) with codeine 120 mg, and 15/35 (43%) with placebo.</P>
<P>
<LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK> reported that 12/34 participants (35%) experienced at least a 50% reduction in pain intensity with codeine 60 mg, and 7/34 (21%) with placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants with visual analogue score (VAS) pain intensity below 30/100 mm</HEADING>
<P>This outcome was not reported in any of the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment group average pain intensity or pain relief</HEADING>
<P>Group mean measures of pain intensity or pain relief were given in six studies (<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>; <LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>; <LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>; <LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>; <LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>; <LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>); these were variously reported as pain intensity assessed on either a VAS, numeric rating scale (NRS), or categorical scale, pain relief measured on a categorical scale, or three- and six-hour summed pain intensity difference (SPID) or total pain relief (TOTPAR). Overall, codeine or codeine plus paracetamol was numerically superior to placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other measures</HEADING>
<P>Three studies reported other measures of pain, including complete or partial pain relief (<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>), maximum attained pain relief (<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>), and participants with 'substantial' pain relief (<LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>). Codeine was numerically superior to placebo.</P>
<P>Four studies reported on the use of rescue medication, as median time to use (<LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>), treatment group mean number of doses daily (<LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>), number of participants using it (<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>), and number using it within six hours (<LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>). Codeine was numerically superior to placebo.</P>
<P>One study presented data on functioning, as a treatment group mean, using a pain disability index (<LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>).</P>
<P>No study presented data on Patient Global Impression of Change.</P>
<P>While there was considerable heterogeneity in the participant characteristics, interventions and outcomes assessed, all but one of the studies (<LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK>) demonstrated superiority of codeine over placebo in at least one outcome measure (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Codeine and codeine plus paracetamol versus active comparators</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Participants with at least 50% reduction in pain</HEADING>
<P>Only two small studies reported this outcome. Both gave single doses of study medication and reported results over six hours.</P>
<P>
<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK> reported that 17/35 participants (49%) experienced at least a 50% reduction in pain intensity with codeine 60 mg, 20/35 (57%) with codeine 120 mg, 14/35 (40%) with benzopyranoperidine 2 mg, and 8/35 (23%) with benzopyranoperidine 4 mg.</P>
<P>
<LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK> reported that 12/34 participants (35%) experienced at least a 50% reduction in pain intensity with codeine 60 mg, and 20/34 (59%) with aspirin 650 mg.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants with VAS pain intensity below 30/100 mm (no worse than mild pain)</HEADING>
<P>Two small studies reported the number of participants who had no worse than mild pain at the end of seven or 21 days of treatment. Since mild pain approximates to &#8804; 30/100 mm on a VAS, we considered these outcomes to be equivalent (<LINK REF="REF-Collins-1997" TYPE="REFERENCE">Collins 1997</LINK>).</P>
<P>In a cross-over study with seven-day treatment periods and medication given six-hourly, <LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK> reported that in the first period 11/21 participants (52%) had no worse than mild pain with codeine 30 mg and 9/23 (39%) with tramadol 40 mg. In the second period 9/16 participants (56%) had no worse than mild pain with codeine and 6/12 (50%) with tramadol.</P>
<P>In a parallel study lasting 23 days, <LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK> reported no worse than mild pain in 41/59 participants (69%) with codeine 150 mg plus paracetamol 2500 mg daily, 40/56 (71%) with tramadol 200 mg daily, and 45/62 (73%) with hydrocodone 25 mg plus paracetamol 2500 mg daily.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment group average pain intensity or pain relief</HEADING>
<P>Group mean measures of pain intensity or pain relief were given in 10 studies (<LINK REF="STD-Beaver-1978-I" TYPE="STUDY">Beaver 1978 I</LINK>; <LINK REF="STD-Beaver-1978-II" TYPE="STUDY">Beaver 1978 II</LINK>; <LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>; <LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>; <LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>; <LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK>; <LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>; <LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>; <LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>; <LINK REF="STD-Staquet-1993" TYPE="STUDY">Staquet 1993</LINK>); these were variously reported as pain intensity assessed on either a VAS, NRS, or a categorical scale, pain relief measured on a categorical scale, or three- and six-hour SPID or TOTPAR. <LINK REF="STD-Beaver-1978-I" TYPE="STUDY">Beaver 1978 I</LINK> compared oral and intramuscular codeine. Active comparators in the other studies were oxycodone, morphine, alclofenac, ciramadol, ketorolac, piroxicam, piroxicam plus codeine, tramadol, THC, NIB, and an experimental drug Z 424. Overall, codeine or codeine plus paracetamol provided levels of analgesia similar to the active comparators at the doses used in both single and multiple dose studies, except that ciramadol and TCH at the higher doses (90 mg and 20 mg respectively) gave numerically better relief (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other measures</HEADING>
<P>
<LINK REF="STD-Beaver-1978-I" TYPE="STUDY">Beaver 1978 I</LINK> and <LINK REF="STD-Beaver-1978-II" TYPE="STUDY">Beaver 1978 II</LINK> tested the relative potency of oral and intramuscular formulations of codeine and of intramuscular codeine, oxycodone and morphine. The relative potency of oral to intramuscular codeine was 0.6 for total analgesic effect, and 0.5 for peak analgesic effect. The relative potency of intramuscular codeine to oxycodone was 0.1 for total analgesic effect and 0.08 for peak analgesic effect.</P>
<P>Three studies reported other measures of pain, including complete or partial pain relief (<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>), maximum attained pain relief (<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>), and participants with 'substantial' pain relief (<LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>). Codeine gave similar results to codeine plus ibuprofen and TCH, and was numerically superior to benzopyranoperidine (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
<P>Three studies reported on the use of rescue medication, as median time to use (<LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>) and number using it within six hours (<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>; <LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>). Ketorolac had a slightly longer time to use of rescue medication than codeine, while fewer participants used rescue medication with codeine than with benzopyranoperidine, and similar numbers with ciramadol and codeine.</P>
<P>No study presented data on functioning or Patient Global Impression of Change.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Proportion of participants with good pain relief with codeine</HEADING>
<P>Summary table A shows the proportion of participants experiencing desirable pain outcomes, i.e. substantial pain relief or at most/no worse than mild pain with codeine, and Summary table B shows mean pain relief with codeine.</P>
<TABLE COLS="6" ROWS="8">
<TR>
<TD COLSPAN="6">
<P>Summary table A: Participants experiencing desirable pain outcomes with codeine</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Study ID</P>
</TH>
<TH ALIGN="CENTER">
<P>Number taking codeine</P>
</TH>
<TH ALIGN="CENTER">
<P>Dose of codeine</P>
</TH>
<TH ALIGN="CENTER">
<P>Duration of treatment</P>
</TH>
<TH ALIGN="CENTER">
<P>Outcome</P>
</TH>
<TH ALIGN="CENTER">
<P>Percentage with outcome</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>18</P>
</TD>
<TD>
<P>30 mg</P>
</TD>
<TD>
<P>single dose</P>
</TD>
<TD>
<P>Partial/complete relief</P>
</TD>
<TD ALIGN="CENTER">
<P>100%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>35</P>
</TD>
<TD>
<P>60, 120 mg</P>
</TD>
<TD>
<P>single dose</P>
</TD>
<TD>
<P>50% pain reduction</P>
</TD>
<TD ALIGN="CENTER">
<P>48%, 57%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>34</P>
</TD>
<TD>
<P>60 mg</P>
</TD>
<TD>
<P>single dose</P>
</TD>
<TD>
<P>50% pain reduction</P>
</TD>
<TD ALIGN="CENTER">
<P>35%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>34</P>
</TD>
<TD>
<P>60, 120 mg</P>
</TD>
<TD>
<P>single dose</P>
</TD>
<TD>
<P>Substantial pain relief (&#8805; 12-point reduction over 7 h, maximum 14)</P>
</TD>
<TD ALIGN="CENTER">
<P>23%, 47%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>41</P>
</TD>
<TD>
<P>Mean 200 mg daily + paracetamol 2000 mg daily</P>
</TD>
<TD>
<P>7 days</P>
</TD>
<TD>
<P>at most mild pain</P>
</TD>
<TD ALIGN="CENTER">
<P>51%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>59</P>
</TD>
<TD>
<P>150 mg daily + paracetamol 2500 mg daily</P>
</TD>
<TD>
<P>21 days</P>
</TD>
<TD>
<P>at most mild pain</P>
</TD>
<TD ALIGN="CENTER">
<P>69%</P>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="6" ROWS="7">
<TR>
<TD COLSPAN="6">
<P>Summary table B: Group mean values of pain relief with codeine</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Study ID</P>
</TH>
<TH ALIGN="CENTER">
<P>Number taking codeine</P>
</TH>
<TH ALIGN="CENTER">
<P>Dose of codeine</P>
</TH>
<TH ALIGN="CENTER">
<P>Duration of treatment</P>
</TH>
<TH ALIGN="CENTER">
<P>Outcome</P>
</TH>
<TH ALIGN="CENTER">
<P>Result</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>18</P>
</TD>
<TD>
<P>30, 60 mg</P>
</TD>
<TD>
<P>1 day</P>
</TD>
<TD>
<P>Pain relief at end of treatment (scale 0-3)</P>
</TD>
<TD>
<P>1.3, 1.3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>33</P>
</TD>
<TD>
<P>240 mg + paracetamol 2400 mg daily</P>
</TD>
<TD>
<P>7 days</P>
</TD>
<TD>
<P>Mean daily pain relief (scale 0-4)</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 3 at all times</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>34</P>
</TD>
<TD>
<P>60, 120 mg</P>
</TD>
<TD>
<P>single dose</P>
</TD>
<TD>
<P>Sum of hourly mean pain relief (scale 0-4) over 7 h (maximum 14 = no pain)</P>
</TD>
<TD ALIGN="CENTER">
<P>9.4, 12.2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>40</P>
</TD>
<TD>
<P>60 mg</P>
</TD>
<TD>
<P>single dose</P>
</TD>
<TD>
<P>Maximum mean pain relief score (scale -1 to +4)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.6</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>18</P>
</TD>
<TD>
<P>30 mg</P>
</TD>
<TD>
<P>single dose</P>
</TD>
<TD>
<P>Maximum mean pain relief score (scale 0 to 4)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.4</P>
</TD>
</TR>
</TABLE>
<P>1. Capretti 1970 included 1/18 participants with Paget's disease.</P>
<P>2. Staquet 1971 included a minority of participants who had chronic pain that was not due to cancer.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events, withdrawals, and deaths</HEADING>
<P>Adverse event reporting was poor; only two studies reported the number of participants with any adverse event specified by treatment group (<LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>; <LINK REF="STD-Staquet-1993" TYPE="STUDY">Staquet 1993</LINK>). Only one study reported (indirectly) on the number of participants experiencing any serious adverse event (<LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>). There were three deaths among the study participants, in all cases these were reported as being due to the underlying malignant diseases (<LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>; <LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>) (see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
<P>Specific adverse events reported in studies with multiple dosing are tabulated in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>. There were too few data for analysis: one study used codeine 30 mg and 60 mg and compared it with two doses of an experimental drug and placebo, three studies used codeine plus paracetamol and compared it with ketorolac, tramadol (two studies), and hydrocodone plus paracetamol, while the other used controlled-release codeine and compared it with placebo. One study treated for one day, three treated for seven days and the other for 21 days. Studies varied in the permitted use of concomitant medication, such as antidepressants, which could influence frequency of adverse events. As expected, nausea, vomiting and constipation were the most commonly reported adverse events, and somnolence and dizziness were frequent in the 21-day study.</P>
<P>Nine studies reported data on withdrawals for any reason (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). Withdrawals, where reported, were fewer than 10% of the study population except in the studies by <LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK> and <LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-07-25 10:09:29 +0100" MODIFIED_BY="Heather Maxwell">
<SUMMARY_OF_RESULTS MODIFIED="2014-07-25 10:09:21 +0100" MODIFIED_BY="Heather Maxwell">
<P>Given the worldwide importance of codeine in cancer pain therapy, the amount of evidence is disappointingly small. Of the 10 placebo-controlled studies included in this review, nine demonstrated the superiority of codeine (in one instance codeine plus paracetamol) compared with placebo in the treatment of cancer pain. There are obvious shortcomings in the evidence available (small study size and other risks of bias, in addition to clinical and methodological heterogeneity between the studies precluding a meaningful pooling of results), but the available data indicate that there is an analgesic effect of codeine in at least some participants with cancer pain over and above that seen with placebo.</P>
<P>Although a number of different drugs or combinations of drugs were compared with codeine, no two studies made the same comparison, and the numbers involved were too small to draw any firm conclusions.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-07-25 10:09:27 +0100" MODIFIED_BY="Heather Maxwell">
<P>We found remarkably few studies that satisfied our fairly broad inclusion criteria, and none in children. A considerable portion of the studies identified were old; eight of the 15 included studies were from the 1970s. Clinical practice has changed considerably since then and some participant characteristics may have been different in the older studies. Furthermore, different cancers may produce different types of pain (pain in different locations, pain mediated via different mechanisms); this is an important factor to consider when applying this evidence in clinical practice.</P>
<P>Eleven of the studies concentrated on the effects of a single dose of medication, although one also had a multiple-dose phase. Single-dose studies may not truly reflect efficacy in clinical practice where multiple dosing will be used, and do not inform adequately on adverse events.</P>
<P>The included studies used a variety of outcomes (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). Few reported on our preferred responder outcomes, 'participants with at least 50% reduction in pain' and 'participants with pain intensity below 30/100 mm on the VAS' (or no worse than mild pain). Use of these responder outcomes (rather than treatment group averages) is important, especially as some participants may be codeine non-responders or poor metabolisers (<LINK REF="REF-Cascarbi-2003" TYPE="REFERENCE">Cascarbi 2003</LINK>), so that significant between-patient heterogeneity in response to codeine can be expected. Information from the other outcomes was also very limited. Although codeine was numerically superior to placebo for analgesic effect in all but one study, the positive effects were generally not seen with the same assessment instruments and at the same observation times. The size of the analgesic effect of codeine in cancer pain and the time-course of the effect, therefore, cannot reliably be determined from the evidence included in this systematic review.</P>
<P>Adverse event reporting was poor, even at the level of reporting the number of participants per treatment arm who experienced any adverse event and serious adverse events. The five multiple dose studies all reported on individual adverse events, but they permitted concomitant use of some established pain treatments such as antidepressants and antiepileptics, which may themselves cause adverse events. Only one study specifically mentioned 'treatment emergent' (new or worsened during treatment) adverse events, which may remove events associated with the established pain treatments, but it is not clear that the reported results are restricted to treatment emergent events (<LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>). The other studies appeared to record all adverse events, although not always in the whole population treated, (<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>; <LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>; <LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>) or any occurrence of particular adverse events (<LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK>).</P>
<P>Codeine is typically recommended at doses between 30 mg and 60 mg for use in mild to moderate pain (step II on the WHO analgesic ladder (<LINK REF="REF-Ventafridda-1985" TYPE="REFERENCE">Ventafridda 1985</LINK>)). For this review, we did not identify any study specifically limited to mild to moderate pain intensity, and none reported results separately for participants with different pain intensities, so there was insufficient evidence to evaluate the suggestion that codeine use should be restricted to mild to moderate pain (<LINK REF="REF-Jadad-1995" TYPE="REFERENCE">Jadad 1995</LINK>). On the other hand, the majority of included studies treated pain of at least moderate intensity, for which codeine appears to be having an analgesic effect.</P>
<P>An analgesic effect of codeine has been shown also in postoperative pain, although codeine does not compare favourably with other commonly used analgesics in these single-dose studies (<LINK REF="REF-Derry-2010" TYPE="REFERENCE">Derry 2010</LINK>). Codeine and paracetamol combined, however, provided good analgesic effect in postoperative pain (<LINK REF="REF-Toms-2009" TYPE="REFERENCE">Toms 2009</LINK>). We identified only three studies examining codeine combined with paracetamol in cancer pain, none of which had a treatment arm using codeine alone. Therefore we do not know whether the analgesic effect is larger than that of codeine used as a single agent.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-07-25 10:09:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>Few studies adequately reported the method used to generate the randomisation sequence, and only one reported on the method of allocation concealment. This may reflect the age of the studies (with about half of them having been published in the 1970s and only three since 2000), rather than necessarily implying poor methodological quality. The majority did report adequately on the methods used to maintain blinding. Five studies were considered at high risk of bias from incomplete outcome data, mainly because they reported results only for participants who completed the study (and withdrawals could not be added back in) and withdrawals exceeded 10% of randomised participants. <LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK> reported adverse events for only 10 of the 18 participants enrolled, without explanation. All but one study was considered at high risk of bias because there were fewer than 50 participants in each of the treatment arms (<LINK REF="REF-N_x00fc_esch-2010" TYPE="REFERENCE">Nüesch 2010</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>We carried out extensive searches, but there may exist some study data that we have not identified. It is possible that sufficient data exist in unidentified studies that do not show an analgesic effect of codeine to overturn the finding of this review. We have tried to be as inclusive as possible while requiring minimum criteria of randomisation, double-blinding, and size (at least 10 participants per treatment arm). We did include two studies with some participants who had pain that was not due to cancer. In <LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK> one of 18 participants had Paget's disease; in <LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK> the proportion of participants with cancer pain is reported only as "a majority". Our intention had been to carry out sensitivity analysis to see whether these studies gave different results, but there were no pooled analyses. Results (both as group means) from these studies, however, are consistent with other studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>In agreement with the present review other reviews discussing codeine for cancer pain also found rather little and low-quality evidence. A review of opioids for cancer pain found poor evidence for codeine (<LINK REF="REF-Koyyalagunta-2012" TYPE="REFERENCE">Koyyalagunta 2012</LINK>). That review included only studies with at least four weeks of treatment and found only one relevant study for codeine; we excluded that study because it was not double-blind (<LINK REF="STD-Mystakidou-2005" TYPE="STUDY">Mystakidou 2005</LINK>).</P>
<P>Quigley found only low-quality evidence indicating that codeine was more effective than placebo for reducing cancer pain at two weeks and reducing the need for rescue medication; there was an increased incidence of nausea. There were insufficient data to compare codeine to other opioids (<LINK REF="REF-Quigley-2008" TYPE="REFERENCE">Quigley 2008</LINK>).</P>
<P>A major guideline recommends the use of weak opioids such as codeine together with a non-opioid analgesic for mild to moderate cancer pain (<LINK REF="REF-SIGN-2008" TYPE="REFERENCE">SIGN 2008</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-07-25 10:09:32 +0100" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>The limited evidence available indicates that codeine may provide good levels of pain relief for some adults with cancer pain. While it is not generally a first line drug in this context in many countries, it is an inexpensive and widely available drug with well-known adverse effects.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-07-25 10:09:32 +0100" MODIFIED_BY="Heather Maxwell">
<P>It is unlikely, for ethical and financial reasons, that randomised controlled trials of adequate size and duration will be carried out to clarify any benefit of codeine compared with placebo. We require good quality trials (randomised, double-blind, and of adequate size and duration) comparing codeine with alternative interventions, such as step II or low dose step III opioids, using patient-centred responder outcomes (participants with at least 50% (or 30%) pain relief or participants with a VAS pain score below 30 mm, or no worse than mild pain). The role of codeine in mild cancer pain, in addition to moderate to severe cancer pain, should be investigated; future studies could increase our understanding by performing separate analyses by baseline pain intensity.</P>
<P>Evaluation of safety and tolerability requires better reporting of treatment emergent adverse events in such trials, potentially supplemented by longer-term cohort studies. Levels of function or disability and quality of life are likely to improve if pain is relieved and adverse events are tolerable, but formal measurement of these outcomes would also help to determine the place of codeine for cancer pain.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-07-25 10:09:36 +0100" MODIFIED_BY="[Empty name]">
<P>Information about codeine and how it might work was based on what had been published in the earlier review of codeine in acute postoperative pain (<LINK REF="REF-Derry-2010" TYPE="REFERENCE">Derry 2010</LINK>) and has been updated for this review.</P>
<P>A standard protocol has been adopted by PaPaS to assess risk of bias in included studies, which is modified to satisfy the requirements of any particular review.</P>
<P>The authors are grateful to Helen Gaskel, Charlotte Rapson, and Rui Wang for helping with papers written in Italian, Spanish, and Chinese, respectively. The authors wish to thank Joanne Abbott for help with the searching.</P>
<P>CRG Funding Acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane PaPaS Group. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-08-01 06:56:17 +0100" MODIFIED_BY="Anna Hobson">
<P>Carmen Straube and Kenneth C Jackson have no competing interests to declare. Scott Strassels has received research funding from Endo Pharmaceuticals and Johnson &amp; Johnson in the past two years. Sebastian Straube has received research support from charities, academic and industry sources at various times and has received fees for presentations in the fields of pain and perinatal medicine; none of this was related to this review. Rae Frances Bell has consulted for Pfizer Norway A/S and Grunenthal A/S in a limited capacity, but this was not related to this review. Sheena Derry and Philip J Wiffen have received research support from charities, government, and industry sources at various times but none related to this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-07-25 10:12:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>Kenneth C Jackson and Philip J Wiffen had written the previous version of the protocol for this review. Sheena Derry and Sebastian Straube updated the protocol, with input from the other authors. Carmen Straube, Sebastian Straube, and Sheena Derry performed the electronic searches. Titles and abstracts of the studies identified were screened by Carmen Straube, Rae F Bell and Sheena Derry. The bibliographies of the identified articles and review articles were screened for other potentially relevant studies by Carmen Straube and Scott Strassels. The full texts of studies deemed appropriate were reviewed by Carmen Straube, Sebastian Straube, Sheena Derry and Philip Wiffen; these authors also graded the study quality and performed the data extraction. Carmen Straube, Sebastian Straube, and Sheena Derry would have performed any data analyses. Carmen Straube and Sebastian Straube drafted the manuscript for the full version of the review, the other authors contributed to the revision of the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-07-25 10:13:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>The protocol of this review intended to include only placebo-controlled studies. We decided to also include active-controlled studies to be more inclusive, because of the ethical problems associated with using placebo in cancer patients (other than in single-dose studies), and to bring the review in line with other completed and planned Cochrane reviews of opioids in cancer pain. These reviews will be included in an overview when completed.</P>
<P>The protocol also stated that we would include only studies in cancer pain, or studies that reported results for cancer pain separately. For the full review, given the paucity of studies, we decided to also include studies where the majority of participants had cancer pain, with the intention of carrying out a sensitivity analysis to determine if this affected the results. As there were no pooled analyses, no sensitivity analysis was done.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2016-06-02 10:13:11 +0100" MODIFIED_BY="Anna Erskine">
<P>A restricted search in June 2016 did not identify any potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. If appropriate, we will update the review if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-06-10 13:17:16 +0100" MODIFIED_BY="Anna Erskine">
<STUDIES MODIFIED="2014-07-22 11:19:32 +0100" MODIFIED_BY="Heather Maxwell">
<INCLUDED_STUDIES MODIFIED="2014-07-22 11:17:00 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Beaver-1978-I" MODIFIED="2014-02-10 11:49:21 +0000" MODIFIED_BY="[Empty name]" NAME="Beaver 1978 I" YEAR="1978">
<REFERENCE MODIFIED="2014-02-10 11:49:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beaver WT, Wallenstein SL, Rogers A, Houde RW</AU>
<TI>Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1978</YR>
<VL>207</VL>
<NO>1</NO>
<PG>92-100</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949265"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949264"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beaver-1978-II" MODIFIED="2014-02-10 11:49:25 +0000" MODIFIED_BY="[Empty name]" NAME="Beaver 1978 II" YEAR="1978">
<REFERENCE MODIFIED="2014-02-10 11:49:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beaver WT, Wallenstein SL, Rogers A, Houde RW</AU>
<TI>Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1978</YR>
<VL>207</VL>
<NO>1</NO>
<PG>101-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949267"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949266"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capretti-1970" MODIFIED="2014-03-20 13:45:50 +0000" MODIFIED_BY="[Empty name]" NAME="Capretti 1970" YEAR="1970">
<REFERENCE MODIFIED="2014-03-20 13:45:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capretti G, Frigerio G</AU>
<TI>Controlled clinical study of the analgesic activity of a new drug (Z. 424) in pain caused by neoplasms</TI>
<TO>Studio clinico controllato dell'attivita analgesica di un nuovo farmaco (Z. 424) nel dolore da neoplasie</TO>
<SO>La Clinica Terapeutica</SO>
<YR>1970</YR>
<VL>52</VL>
<NO>4</NO>
<PG>361-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949269"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949268"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlson-1990" MODIFIED="2013-11-21 13:27:56 +0000" MODIFIED_BY="[Empty name]" NAME="Carlson 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-11-21 13:27:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlson RW, Borrison RA, Sher HB, Eisenberg PD, Mowry PA, Wolin EM</AU>
<TI>A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain</TI>
<SO>Pharmacotherapy</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>3</NO>
<PG>211-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949271"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949270"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003" MODIFIED="2014-02-12 21:22:13 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-02-12 21:22:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen Y, Zhu W, Liang H, Wu G</AU>
<TI>The analgesic effect of ibuprofen-codeine sustained release tablets on postoperative and cancer pain</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1290-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949273"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949272"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dhaliwal-1995" MODIFIED="2014-02-12 21:22:43 +0000" MODIFIED_BY="[Empty name]" NAME="Dhaliwal 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-02-12 21:22:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dhaliwal HS, Sloan P, Arkinstall WW, Thirlwell MP, Babul N, Harsanyi Z, et al</AU>
<TI>Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>8</NO>
<PG>612-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949275"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949274"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jochimsen-1978-I" MODIFIED="2014-02-12 21:23:05 +0000" MODIFIED_BY="[Empty name]" NAME="Jochimsen 1978 I" YEAR="1978">
<REFERENCE MODIFIED="2014-02-12 21:23:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jochimsen PR, Lawton RL, VerSteeg K, Noyes R Jr</AU>
<TI>Effect of benzopyranoperidine, a delta-9-THC congener, on pain</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1978</YR>
<VL>24</VL>
<NO>2</NO>
<PG>223-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949277"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949276"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moertel-1971" MODIFIED="2013-11-21 13:38:12 +0000" MODIFIED_BY="[Empty name]" NAME="Moertel 1971" YEAR="1971">
<REFERENCE MODIFIED="2013-11-21 13:38:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moertel CG, Ahmann DL, Taylor WF, Schwartau N</AU>
<TI>Aspirin and pancreatic cancer pain</TI>
<SO>Gastroenterology</SO>
<YR>1971</YR>
<VL>60</VL>
<NO>4</NO>
<PG>552-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949279"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949278"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noyes-1975" MODIFIED="2014-02-12 21:23:22 +0000" MODIFIED_BY="[Empty name]" NAME="Noyes 1975" YEAR="1975">
<REFERENCE MODIFIED="2014-02-12 21:23:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noyes R Jr, Brunk SF, Avery DA, Canter AC</AU>
<TI>The analgesic properties of delta-9-tetrahydrocannabinol and codeine</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1975</YR>
<VL>18</VL>
<NO>1</NO>
<PG>84-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949281"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949280"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rico-2000" MODIFIED="2014-02-19 12:27:54 +0000" MODIFIED_BY="[Empty name]" NAME="Rico 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-02-19 12:27:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rico MA, Cura MA, Harbst H, Palominos A, Figueroa M, Kramer V</AU>
<TI>Assessment of tramadol as an alternative opioid instead of codeine at the second step of the WHO analgesic scale</TI>
<TO>Evaluación de tramadol como un opioide alternativoa la codeína en el segundo peldaño de la escalera analgésica de la OMS</TO>
<SO>Revista de la Sociedad Espanola del Dolor</SO>
<YR>2000</YR>
<VL>7</VL>
<PG>345-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949283"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949282"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-2007" MODIFIED="2014-07-22 11:16:02 +0100" MODIFIED_BY="Heather Maxwell" NAME="Rodriguez 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-07-22 11:16:02 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez RF, Bravo LE, Castro F, Montoya O, Castillo JM, Castillo MP, et al</AU>
<TI>Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial</TI>
<SO>Journal of Palliative Medicine</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>1</NO>
<PG>56-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949285"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-10 11:58:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez RF, Castillo JM, Castillo MP, Montoya O, Daza P, Rodríguez MF, et al</AU>
<TI>Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS MODIFIED="2014-02-10 11:58:02 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949286"/><IDENTIFIER MODIFIED="2014-02-10 11:58:02 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1097/AJP.0b013e318156ca4d"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-10 11:53:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez RF, Castillo JM, Del Pilar Castillo M, Nuñez PD, Rodriguez MF, Restrepo JM, et al</AU>
<TI>Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>4</NO>
<PG>581-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949287"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949284"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stambaugh-1987" MODIFIED="2013-11-21 13:44:01 +0000" MODIFIED_BY="[Empty name]" NAME="Stambaugh 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-11-21 13:43:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stambaugh JE Jr, McAdams J</AU>
<TI>Comparison of the analgesic efficacy and safety oral ciramadol, codeine, and placebo in patients with chronic cancer pain</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1987</YR>
<VL>27</VL>
<NO>2</NO>
<PG>162-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949289"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949288"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staquet-1971" MODIFIED="2014-07-22 11:17:00 +0100" MODIFIED_BY="Heather Maxwell" NAME="Staquet 1971" YEAR="1971">
<REFERENCE MODIFIED="2014-07-22 11:17:00 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staquet M, Luyckx A, Van Cauwenberge H</AU>
<TI>A double-blind comparison of alclofenac, pentazocine, and codeine with placebo control in pathologic pain</TI>
<SO>Journal of Clinical Pharmacology and New Drugs</SO>
<YR>1971</YR>
<VL>11</VL>
<NO>6</NO>
<PG>450-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949291"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949290"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staquet-1978" MODIFIED="2014-02-12 21:24:23 +0000" MODIFIED_BY="[Empty name]" NAME="Staquet 1978" YEAR="1978">
<REFERENCE MODIFIED="2014-02-12 21:24:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staquet M, Gantt C, Machin D</AU>
<TI>Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1978</YR>
<VL>23</VL>
<NO>4</NO>
<PG>397-401</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949293"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949292"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staquet-1993" MODIFIED="2014-02-10 12:16:58 +0000" MODIFIED_BY="[Empty name]" NAME="Staquet 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-02-10 12:15:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staquet M, Renaud A</AU>
<TI>Double-blind randomized trial of piroxicam and codeine in cancer pain</TI>
<SO>Current Theraputics and Research</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>4</NO>
<PG>435-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949295"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949294"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-07-22 11:19:32 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Chary-1994" MODIFIED="2014-02-10 11:49:49 +0000" MODIFIED_BY="[Empty name]" NAME="Chary 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-02-10 11:49:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chary S, Goughnour BR, Moulin DE, Thorpe WR, Harsanyi Z, Darke AC</AU>
<TI>The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>6</NO>
<PG>363-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949297"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949296"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corgill-1965" MODIFIED="2014-07-22 11:19:08 +0100" MODIFIED_BY="Heather Maxwell" NAME="Corgill 1965" YEAR="1965">
<REFERENCE MODIFIED="2014-07-22 11:19:08 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corgill DA, Ligon CW, Defelice EA</AU>
<TI>Double-blind comparison of namoxyrate, codeine, aspirin, and placebo</TI>
<SO>Current Therapeutic Research: Clinical and Experimental</SO>
<YR>1965</YR>
<VL>7</VL>
<NO>5</NO>
<PG>263-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949299"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949298"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Conno-1991" MODIFIED="2014-07-22 11:19:32 +0100" MODIFIED_BY="Heather Maxwell" NAME="De Conno 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-07-22 11:19:32 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Conno F, Ripamonti C, Sbanotto A, Barletta L, Zecca E, Martini C, et al</AU>
<TI>A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>7</NO>
<PG>423-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949301"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949300"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jochimsen-1978-II" MODIFIED="2013-11-21 14:05:09 +0000" MODIFIED_BY="[Empty name]" NAME="Jochimsen 1978 II" YEAR="1978">
<REFERENCE MODIFIED="2013-11-21 14:05:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jochimsen PR, Noyes R Jr</AU>
<TI>Appraisal of codeine as an analgesic in older patients</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1978</YR>
<VL>26</VL>
<NO>11</NO>
<PG>521-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949303"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-21 14:03:18 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949302"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kantor-1966" MODIFIED="2013-11-22 09:37:47 +0000" MODIFIED_BY="[Empty name]" NAME="Kantor 1966" YEAR="1966">
<REFERENCE MODIFIED="2013-11-22 09:37:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kantor TG, Sunshine A, Laska E, Meisner M, Hopper M</AU>
<TI>Oral analgesic studies: pentazocine hydrochloride, codeine, aspirin, and placebo and their influence on response to placebo</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1966</YR>
<VL>7</VL>
<NO>4</NO>
<PG>447-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949305"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949304"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinetti-1970" MODIFIED="2013-12-17 08:16:03 +0000" MODIFIED_BY="[Empty name]" NAME="Martinetti 1970" YEAR="1970">
<REFERENCE MODIFIED="2013-12-17 08:16:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinetti L, Lodola E, Monafo V, Ferrari V</AU>
<TI>Clinical evaluation of an oral analgesic, Z.424, in patients with chronic pain</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1970</YR>
<VL>10</VL>
<NO>6</NO>
<PG>390-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949307"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949306"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minotti-1989" MODIFIED="2014-02-12 21:26:12 +0000" MODIFIED_BY="[Empty name]" NAME="Minotti 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-02-12 21:26:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minotti V, Patoia L, Roila F, Basurto C, Tonato M, Pasqualucci V, et al</AU>
<TI>Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain</TI>
<SO>Pain</SO>
<YR>1989</YR>
<VL>36</VL>
<NO>2</NO>
<PG>177-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949309"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949308"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minotti-1998" MODIFIED="2014-02-12 21:26:40 +0000" MODIFIED_BY="[Empty name]" NAME="Minotti 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-02-12 21:26:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minotti V, De Angelis V, Righetti E, Celani MG, Rossetti R, Lupatelli M, et al</AU>
<TI>Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain</TI>
<SO>Pain</SO>
<YR>1998</YR>
<VL>74</VL>
<NO>2-3</NO>
<PG>133-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949311"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949310"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mystakidou-2005" MODIFIED="2013-11-21 14:15:21 +0000" MODIFIED_BY="[Empty name]" NAME="Mystakidou 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-11-21 14:15:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mystakidou K, Katsouda E, Kouloulias V, Kouvaris J, Tsiatas M, Vlahos L</AU>
<TI>Comparison of transdermal fentanyl with codeine/paracetamol, in combination with radiotherapy, for the management of metastatic bone pain</TI>
<SO>Journal of Opioid Management</SO>
<YR>2005</YR>
<VL>1</VL>
<NO>4</NO>
<PG>2004-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949313"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949312"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pistevou_x002d_Gompaki-2004" MODIFIED="2014-02-12 21:27:13 +0000" MODIFIED_BY="[Empty name]" NAME="Pistevou-Gompaki 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-02-12 21:27:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pistevou-Gompaki K, Kouloulias VE, Varveris C, Mystakidou K, Georgakopoulos G, Eleftheriadis N, et al</AU>
<TI>Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>2</NO>
<PG>159-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949315"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949314"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sniezek--2011" MODIFIED="2013-11-21 14:30:22 +0000" MODIFIED_BY="[Empty name]" NAME="Sniezek  2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-21 14:30:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sniezek PJ, Brodland DG, Zitelli JA</AU>
<TI>A randomized controlled trial comparing acetaminophen, acetaminophen and ibuprofen, and acetaminophen and codeine for postoperative pain relief after Mohs surgery and cutaneous reconstruction</TI>
<SO>Dermatologic Surgery</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>7</NO>
<PG>1007-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949317"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949316"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stambaugh-1980" MODIFIED="2014-04-25 14:05:26 +0100" MODIFIED_BY="[Empty name]" NAME="Stambaugh 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-04-25 14:05:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stambaugh JE Jr</AU>
<TI>Analgesic Equivalence of Tylox® and Percodan®: double-blind crossover study of patients with pain from malignancy</TI>
<SO>Current Therapeutic Research</SO>
<YR>1980</YR>
<VL>27</VL>
<NO>2</NO>
<PG>302-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949319"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949318"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunshine-1988" MODIFIED="2013-11-21 14:45:53 +0000" MODIFIED_BY="[Empty name]" NAME="Sunshine 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-11-21 14:45:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunshine A, Olson NZ</AU>
<TI>Analgesic efficacy of ketoprofen in postpartum, general surgery, and chronic cancer pain</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1988</YR>
<VL>28</VL>
<NO>12 Suppl</NO>
<PG>S47-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949321"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949320"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watanabe-2008" MODIFIED="2013-11-21 14:48:24 +0000" MODIFIED_BY="[Empty name]" NAME="Watanabe 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-21 14:48:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe S, Pereira J, Tarumi Y, Hanson J, Bruera E</AU>
<TI>A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain</TI>
<SO>Journal of Palliative Medicine</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>4</NO>
<PG>570-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2949323"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2949322"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-07-22 12:16:40 +0100" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2014-07-22 12:16:40 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Bennett-2003" MODIFIED="2012-10-26 11:41:53 +0100" MODIFIED_BY="[Empty name]" NAME="Bennett 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bennett M, Cresswell H</AU>
<TI>Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning</TI>
<SO>Palliative Medicine</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>5</NO>
<PG>418-22</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:41:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:41:53 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1191/0269216303pm773oa"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-BNF-2014" MODIFIED="2014-03-20 18:10:35 +0000" MODIFIED_BY="Phil Wiffen" NAME="BNF 2014" TYPE="OTHER">
<AU>Joint Formulary Committee</AU>
<TI>British National Formulary (online)</TI>
<SO>www.medicinescomplete.com (Accessed on 5 March 2014)</SO>
<PB>BMJ Group and Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caraceni-2012" MODIFIED="2013-03-25 17:22:55 +0000" MODIFIED_BY="[Empty name]" NAME="Caraceni 2012" TYPE="JOURNAL_ARTICLE">
<AU>Caraceni A, Hanks G, Kaasa S, Bennett M, Brunelli C, Cherny N, et al, for the European Palliative Research Collaborative (EPCRC), on behalf of the European Association for Palliative Care (EAPC)</AU>
<TI>Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC</TI>
<SO>Lancet Oncology</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>2</NO>
<PG>e58-68</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:05:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:05:19 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S1470-2045(12)70040-2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cascarbi-2003" MODIFIED="2013-03-25 17:23:00 +0000" MODIFIED_BY="[Empty name]" NAME="Cascarbi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cascarbi I</AU>
<TI>Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>2003</YR>
<VL>33 Suppl 2</VL>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ciszkowski-2009" MODIFIED="2012-11-13 07:05:49 +0000" MODIFIED_BY="[Empty name]" NAME="Ciszkowski 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G</AU>
<TI>Codeine, ultrarapid-metabolism genotype, and postoperative death</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>361</VL>
<NO>8</NO>
<PG>827-8</PG>
<IDENTIFIERS MODIFIED="2012-11-13 07:05:49 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-11-13 07:05:49 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1056/NEJMc0904266"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collins-1997" MODIFIED="2014-02-25 09:33:43 +0000" MODIFIED_BY="[Empty name]" NAME="Collins 1997" TYPE="JOURNAL_ARTICLE">
<AU>Collins SL, Moore RA, McQuay HJ</AU>
<TI>The visual analogue pain intensity scale: what is moderate pain in millimetres?</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>72</VL>
<NO>1-2</NO>
<PG>95-7</PG>
<IDENTIFIERS MODIFIED="2014-02-25 09:33:43 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-02-25 09:33:43 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0304-3959(97)00005-5"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cook-1995" MODIFIED="2012-10-26 11:12:41 +0100" MODIFIED_BY="[Empty name]" NAME="Cook 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cook RJ, Sackett DL</AU>
<TI>The number needed to treat: a clinically useful measure of treatment effect</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>310</VL>
<NO>6977</NO>
<PG>452-4</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:12:41 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:12:41 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmj.310.6977.452"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-Conno-2003" MODIFIED="2012-10-26 11:15:58 +0100" MODIFIED_BY="Jessica R Thomas" NAME="De Conno 2003" TYPE="JOURNAL_ARTICLE">
<AU>De Conno F, Panzeri C, Brunelli C, Saita L, Ripamonti C</AU>
<TI>Palliative care in a national cancer center: results in 1987 versus 1993 versus 2000</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>6</NO>
<PG>499-511</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:14:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:14:09 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0885-3924(03)00069-1"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Derry-2010" MODIFIED="2012-11-13 12:39:37 +0000" MODIFIED_BY="[Empty name]" NAME="Derry 2010" TYPE="COCHRANE_REVIEW">
<AU>Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral codeine, as a single agent, for acute postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-11-13 07:28:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-11-13 07:28:46 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008099.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2008" MODIFIED="2012-10-26 11:18:53 +0100" MODIFIED_BY="[Empty name]" NAME="Dworkin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al</AU>
<TI>Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>Journal of Pain</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>2</NO>
<PG>105-21</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:18:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:18:53 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.jpain.2007.09.005"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hadley-2013" MODIFIED="2014-02-12 21:44:09 +0000" MODIFIED_BY="[Empty name]" NAME="Hadley 2013" TYPE="COCHRANE_REVIEW">
<AU>Hadley G, Derry S, Moore RA, Wiffen PJ</AU>
<TI>Transdermal fentanyl for cancer pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2014-02-12 21:44:09 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-02-12 21:44:09 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010270.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-10-08 14:02:13 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Altman DG, Antes G, Gøtzsche P, Higgins JPT, Jüni P, Lewis S, et al</AU>
<TI>Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Altman DG, Sterne JAC</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jackson-2001" MODIFIED="2014-07-22 11:23:42 +0100" MODIFIED_BY="Heather Maxwell" NAME="Jackson 2001" TYPE="BOOK_SECTION">
<AU>Jackson KC, Lipman AG</AU>
<TI>Opioid analgesics</TI>
<SO>Practical Pain Management, 3rd Ed</SO>
<YR>2001</YR>
<ED>Tollison CD, Satterthwaite JR, Tollison JW</ED>
<PB>Lippincott, Williams, and Wilkins</PB>
<CY>Baltimore, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacox-1994" MODIFIED="2014-07-22 11:24:20 +0100" MODIFIED_BY="Heather Maxwell" NAME="Jacox 1994" TYPE="BOOK">
<AU>Jacox A, Carr DB, Payne R, Berde CB, Brietbart W, Cain JM, et al</AU>
<SO>Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592</SO>
<YR>1994</YR>
<PB>Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1995" MODIFIED="2012-10-26 11:27:34 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1995" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Browman GP</AU>
<TI>The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<PG>1870-3</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:27:34 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:27:34 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1001/jama.1995.03530230056031"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2012-10-26 11:29:02 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:29:02 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:29:02 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/0197-2456(95)00134-4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koyyalagunta-2012" MODIFIED="2014-02-28 14:34:07 +0000" MODIFIED_BY="[Empty name]" NAME="Koyyalagunta 2012" TYPE="JOURNAL_ARTICLE">
<AU>Koyyalagunta D, Bruera E, Solanki DR, Nouri KH, Burton AW, Toro MP, et al</AU>
<TI>A systematic review of randomized trials on the effectiveness of opioids for cancer pain</TI>
<SO>Pain Physician</SO>
<YR>2012</YR>
<VL>15 (3 Suppl)</VL>
<PG>ES39-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuehn-2013" MODIFIED="2014-04-09 14:16:47 +0100" MODIFIED_BY="[Empty name]" NAME="Kuehn 2013" TYPE="JOURNAL_ARTICLE">
<AU>Kuehn BM</AU>
<TI>FDA: No codeine after tonsillectomy for children</TI>
<SO>JAMA</SO>
<YR>2013</YR>
<VL>309</VL>
<NO>11</NO>
<PG>1100</PG>
<IDENTIFIERS MODIFIED="2014-04-09 14:16:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-04-09 14:16:47 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1001/jama.2013.2403"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-L_x0027_Abb_x00e9_-1987" MODIFIED="2012-10-26 10:57:33 +0100" MODIFIED_BY="[Empty name]" NAME="L'Abbé 1987" TYPE="JOURNAL_ARTICLE">
<AU>L'Abbé KA, Detsky AS, O'Rourke K</AU>
<TI>Meta-analysis in clinical research</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>107</VL>
<PG>224-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Madadi-2007" MODIFIED="2012-11-13 12:47:35 +0000" MODIFIED_BY="[Empty name]" NAME="Madadi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder JS, et al</AU>
<TI>Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine</TI>
<SO>Canadian Family Physician</SO>
<YR>2007</YR>
<VL>53</VL>
<NO>1</NO>
<PG>33-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNicol-2005" MODIFIED="2012-11-13 12:43:13 +0000" MODIFIED_BY="Jessica R Thomas" NAME="McNicol 2005" TYPE="COCHRANE_REVIEW">
<AU>McNicol E, Strassels SA, Goudas L, Lau J, Carr DB</AU>
<TI>NSAIDS or paracetamol, alone or combined with opioids, for cancer pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-07 20:53:49 +0000" MODIFIED_BY="Jessica R Thomas"><IDENTIFIER MODIFIED="2008-11-07 20:53:49 +0000" MODIFIED_BY="Jessica R Thomas" TYPE="DOI" VALUE="10.1002/14651858.CD005180"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1998" MODIFIED="2014-07-22 11:25:40 +0100" MODIFIED_BY="Heather Maxwell" NAME="McQuay 1998" TYPE="BOOK">
<AU>McQuay HJ, Moore RA</AU>
<SO>An Evidence-Based Resource for Pain Relief</SO>
<YR>1998</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2012-10-25 14:10:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Miaskowski-2005" MODIFIED="2014-07-22 11:26:28 +0100" MODIFIED_BY="Heather Maxwell" NAME="Miaskowski 2005" TYPE="BOOK">
<AU>Miaskowski C, Cleary J, Burney R, Coyne P, Finley R, Foster R, et al</AU>
<SO>Guideline for the Management of Cancer Pain in Adults and Children, APS Clinical Practice Guideline Series, No. 3</SO>
<YR>2005</YR>
<PB>American Pain Society</PB>
<CY>Glenview, IL</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1998" MODIFIED="2012-10-26 11:32:49 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ</AU>
<TI>Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects</TI>
<SO>Pain</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>3</NO>
<PG>209-16</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:32:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:32:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0304-3959(98)00140-7"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2010" MODIFIED="2012-10-26 11:42:19 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al; ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief; Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors</AU>
<TI>"Evidence" in chronic pain &#8211; establishing best practice in the reporting of systematic reviews</TI>
<SO>Pain</SO>
<YR>2010</YR>
<VL>150</VL>
<NO>3</NO>
<PG>386-9</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:36:01 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:36:01 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.pain.2010.05.011"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2013" MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" NAME="Moore 2013" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Derry S, Wiffen PJ</AU>
<TI>Challenges in design and interpretation of chronic pain trials</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2013</YR>
<VL>111</VL>
<NO>1</NO>
<PG>38-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morris-1995" MODIFIED="2014-07-22 11:27:44 +0100" MODIFIED_BY="Heather Maxwell" NAME="Morris 1995" TYPE="BOOK_SECTION">
<AU>Morris JA, Gardner MJ</AU>
<TI>Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates</TI>
<SO>Statistics with Confidence - Confidence Intervals and Statistical Guidelines</SO>
<YR>1995</YR>
<PG>50-63</PG>
<ED>Gardner MJ, Altman DG</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicholson-2007" MODIFIED="2012-11-13 07:17:47 +0000" MODIFIED_BY="[Empty name]" NAME="Nicholson 2007" TYPE="COCHRANE_REVIEW">
<AU>Nicholson AB</AU>
<TI>Methadone for cancer pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-11-13 07:17:47 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-11-13 07:17:47 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003971.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-N_x00fc_esch-2010" MODIFIED="2014-02-19 12:34:58 +0000" MODIFIED_BY="[Empty name]" NAME="Nüesch 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al</AU>
<TI>Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>341</VL>
<PG>c3515</PG>
<IDENTIFIERS MODIFIED="2014-02-19 12:34:25 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-02-19 12:34:25 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmj.c3515"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Opiates-2013" MODIFIED="2014-01-03 14:35:18 +0000" MODIFIED_BY="[Empty name]" NAME="Opiates 2013" TYPE="OTHER">
<AU>Anon</AU>
<TI>Codeine</TI>
<SO>www.opiates.com/codeine/ (Accessed 3 Jan 2014)</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paul-1989" MODIFIED="2013-02-13 10:10:59 +0000" MODIFIED_BY="[Empty name]" NAME="Paul 1989" TYPE="JOURNAL_ARTICLE">
<AU>Paul D, Standifer KM, Inturrisi CE, Pasternak GW</AU>
<TI>Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1989</YR>
<VL>251</VL>
<NO>2</NO>
<PG>477-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PCA-2013" MODIFIED="2014-01-03 09:22:05 +0000" MODIFIED_BY="[Empty name]" NAME="PCA 2013" TYPE="BOOK">
<AU>Health and Social Care Information Centre, Prescribing and Primary Care</AU>
<SO>Prescription Cost Analysis, England 2012</SO>
<YR>2013</YR>
<PB>The Health and Social Care Information Centre</PB>
<IDENTIFIERS MODIFIED="2014-01-03 09:22:05 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-01-03 09:22:05 +0000" MODIFIED_BY="[Empty name]" OTHERTYPE="ISBN" TYPE="OTHER" VALUE="978-1-84-636859-2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Quigley-2008" MODIFIED="2014-02-28 14:53:34 +0000" MODIFIED_BY="[Empty name]" NAME="Quigley 2008" TYPE="JOURNAL_ARTICLE">
<AU>Quigley C</AU>
<TI>Opioids in people with cancer-related pain</TI>
<SO>Clinical Evidence (Online)</SO>
<YR>2008</YR>
<VL>Jul 31</VL>
<PG>2408</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RCPCH-2013" MODIFIED="2014-04-24 17:06:53 +0100" MODIFIED_BY="[Empty name]" NAME="RCPCH 2013" TYPE="OTHER">
<TI>Guidance for the Use of Codeine in Children</TI>
<SO>Royal College of Anaesthetists, Association of Paediatric Anaesthetists of Great Britain and Ireland, Joint Medicines Committee of the Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group.</SO>
<YR>2013</YR>
<IDENTIFIERS MODIFIED="2014-04-24 17:06:53 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-04-24 17:06:53 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.rcpch.ac.uk/system/files/protected/news/Codeine-statement-RCPCH-NPPG-RCoA-2013-11.pdf (accessed 24 April 2014)"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2014-04-11 14:30:55 +0100" MODIFIED_BY="Anna Hobson" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ripamonti-2012-I" MODIFIED="2014-02-12 21:40:20 +0000" MODIFIED_BY="[Empty name]" NAME="Ripamonti 2012 I" TYPE="JOURNAL_ARTICLE">
<AU>Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F; ESMO Guidelines Working Group</AU>
<TI>Management of cancer pain: ESMO Clinical Practice Guidelines</TI>
<SO>Annals of Oncology</SO>
<YR>2012</YR>
<VL>23 (Suppl 7)</VL>
<PG>vii139-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ripamonti-2012-II" MODIFIED="2014-02-12 21:40:57 +0000" MODIFIED_BY="[Empty name]" NAME="Ripamonti 2012 II" TYPE="JOURNAL_ARTICLE">
<AU>Ripamonti CI</AU>
<TI>Pain management</TI>
<SO>Annals of Oncology</SO>
<YR>2012</YR>
<VL>23 (Suppl 10)</VL>
<PG>x294-x301</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:37:28 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:37:28 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/annonc/mds360"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2008" MODIFIED="2014-07-22 11:36:32 +0100" MODIFIED_BY="Heather Maxwell" NAME="SIGN 2008" TYPE="BOOK">
<AU>Scottish Intercollegiate Guidelines Network</AU>
<SO>Control of pain in adults with cancer. A national clinical guideline</SO>
<YR>2008</YR>
<PB>Scottish Intercollegiate Guidelines Network</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS MODIFIED="2014-03-13 08:08:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Straube-2008" MODIFIED="2013-03-25 17:23:34 +0000" MODIFIED_BY="[Empty name]" NAME="Straube 2008" TYPE="JOURNAL_ARTICLE">
<AU>Straube S, Derry S, McQuay HJ, Moore RA</AU>
<TI>Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2008</YR>
<VL>66</VL>
<NO>2</NO>
<PG>266-75</PG>
<IDENTIFIERS MODIFIED="2012-10-26 11:38:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-10-26 11:38:24 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1365-2125.2008.03200.x"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Toms-2009" MODIFIED="2012-11-13 07:31:16 +0000" MODIFIED_BY="[Empty name]" NAME="Toms 2009" TYPE="COCHRANE_REVIEW">
<AU>Toms L, Derry S, Moore RA, McQuay HJ</AU>
<TI>Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-11-13 07:31:16 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-11-13 07:31:16 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001547.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-den-Beuken_x002d_van-Everdingen-2007" MODIFIED="2012-11-13 07:39:27 +0000" MODIFIED_BY="[Empty name]" NAME="van den Beuken-van Everdingen 2007" TYPE="JOURNAL_ARTICLE">
<AU>van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J</AU>
<TI>Prevalence of pain in patients with cancer: a systematic review of the past 40 years</TI>
<SO>Annals of Oncology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>9</NO>
<PG>1437-49</PG>
<IDENTIFIERS MODIFIED="2012-11-13 07:39:27 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-11-13 07:39:27 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/annonc/mdm056"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ventafridda-1985" MODIFIED="2014-03-05 11:55:19 +0000" MODIFIED_BY="Phil Wiffen" NAME="Ventafridda 1985" TYPE="JOURNAL_ARTICLE">
<AU>Ventafridda V, Saita L, Ripamonti C, De Conno F</AU>
<TI>WHO guidelines for the use of analgesics in cancer pain</TI>
<SO>International Journal of Tissue Reactions</SO>
<YR>1985</YR>
<VL>7</VL>
<PG>93-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1996" MODIFIED="2014-07-22 12:16:03 +0100" MODIFIED_BY="Heather Maxwell" NAME="WHO 1996" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>WHO Cancer Pain Relief - a guide to opioid availability, 2nd Edition</SO>
<YR>1996</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2012" MODIFIED="2014-07-22 12:16:40 +0100" MODIFIED_BY="Heather Maxwell" NAME="WHO 2012" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses</SO>
<YR>2012</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS MODIFIED="2012-11-06 14:17:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wiffen-2013" MODIFIED="2014-01-03 08:59:01 +0000" MODIFIED_BY="[Empty name]" NAME="Wiffen 2013" TYPE="COCHRANE_REVIEW">
<AU>Wiffen PJ, Wee B, Moore RA</AU>
<TI>Oral morphine for cancer pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2014-01-03 08:59:01 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-01-03 08:59:01 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003868.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wittwer-2006" MODIFIED="2013-02-13 10:01:46 +0000" MODIFIED_BY="[Empty name]" NAME="Wittwer 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wittwer E, Kern SE</AU>
<TI>Role of morphine's metabolites in analgesia: concepts and controversies</TI>
<SO>The AAPS Journal</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>2</NO>
<PG>E348-52</PG>
<IDENTIFIERS MODIFIED="2013-02-13 10:01:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-02-13 10:01:30 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/BF02854905"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-07-23 16:14:19 +0100" MODIFIED_BY="Heather Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-07-23 16:14:19 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-07-22 16:07:43 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Beaver-1978-I">
<CHAR_METHODS MODIFIED="2014-02-12 10:07:48 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, four-way cross-over of oral and intramuscular codeine (also of oral and intramuscular oxycodone). Single dose, 6-hour observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-12 10:07:53 +0000" MODIFIED_BY="[Empty name]">
<P>Participants with malignant tumours, with moderate or severe pain at least 3 hours after last routine analgesic medication</P>
<P>Codeine: N = 38 (some participants completed more than one set of cross-overs)</P>
<P>(Oxycodone: N = 14 (some participants completed more than one set of cross-overs))</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-12 09:51:12 +0000" MODIFIED_BY="[Empty name]">
<P>Codeine</P>
<P>Series 1: 30 mg IM, 60 mg IM, 60 mg oral, 120 mg oral</P>
<P>Series 2: 60 mg IM, 180 mg IM, 120 mg oral, 360 mg oral</P>
<P>(Oxycodone: 5 mg IM, 15 mg IM, 10 mg oral, 30 mg oral)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-28 08:41:06 +0000" MODIFIED_BY="[Empty name]">
<P>Four-point PI scale (0-3)</P>
<P>Five-point PR scale (0-4)</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-22 16:07:43 +0100" MODIFIED_BY="Heather Maxwell">
<P>Oxford Quality Score: R = 1, DB = 2, W = 0. Total = 3/5</P>
<P>Funding: Committee on Problems of Drug Dependence, National Academy of Sciences, National Research Council, "a group of interested pharmaceutical manufacturers", National Cancer Institute, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:52:46 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Beaver-1978-II">
<CHAR_METHODS MODIFIED="2014-02-12 10:08:06 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, four-way cross-over of intramuscular codeine and oxycodone and morphine (and also intramuscular morphine and oxycodone). Single dose, 6-hour observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-12 10:08:11 +0000" MODIFIED_BY="[Empty name]">
<P>Participants with malignant tumours, with moderate or severe pain at least 3 hours after last routine analgesic medication</P>
<P>Codeine N = 28 (some participants completed more than one set of cross-overs)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-12 19:58:43 +0000" MODIFIED_BY="[Empty name]">
<P>Codeine</P>
<P>Series 1: IM codeine 90 mg, codeine 180 mg, oxycodone 7.5 mg, oxycodone 15 mg, morphine 16 mg</P>
<P>Series 2: IM codeine 90 mg, codeine 180 mg, oxycodone 15 mg, oxycodone 30 mg, morphine 16 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-28 08:41:12 +0000" MODIFIED_BY="[Empty name]">
<P>Four-point PI scale (0-3)</P>
<P>Five-point PR scale (0-4)</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:52:46 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 1, W = 0. Total = 2/5</P>
<P>Funding: Committee on Problems of Drug Dependence, National Academy of Sciences, National Research Council, "a group of interested pharmaceutical manufacturers", National Cancer Institute, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-22 16:10:31 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Capretti-1970">
<CHAR_METHODS MODIFIED="2014-07-22 16:10:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>RCT, five-way cross-over; duration of treatment for each drug was 1 day, with four doses of test drug taken</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-25 13:49:20 +0100" MODIFIED_BY="Anna Hobson">
<P>Hospitalised with skeletal abnormalities and pain due to malignant tumours (1 participant had Paget's Disease)</P>
<P>N = 18</P>
<P>All women</P>
<P>Mean age 55 years (23 to 77)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-20 14:04:26 +0000" MODIFIED_BY="[Empty name]">
<P>Codeine 30 mg x 4 daily</P>
<P>Codeine 60 mg x 4 daily</P>
<P>Z 424 50 mg x 4 daily</P>
<P>Z 424 100 mg x 4 daily</P>
<P>Placebo</P>
<P>Rescue medication not mentioned</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-28 08:41:20 +0000" MODIFIED_BY="[Empty name]">
<P>Four-point PI scale (0-3)</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 2, W = 0. Total = 2/5</P>
<P>Funding: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Carlson-1990">
<CHAR_METHODS MODIFIED="2014-01-24 14:41:22 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, parallel group, first-dose 6-hour observation period in which patients were randomised to ketorolac, paracetamol plus codeine, or placebo. Thereafter participants receiving placebo were reassigned to one of the two active treatments and observed for 7 days with drugs taken 4 times daily</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-24 14:41:20 +0000" MODIFIED_BY="[Empty name]">
<P>75 participants (32 women, 43 men; mean age: 62.2 years) with moderate to severe cancer pain; histologically confirmed diagnosis of cancer (most common types: genitourinary, lung, breast, gastrointestinal)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-03 14:22:53 +0000" MODIFIED_BY="[Empty name]">
<P>First-dose 6-hour observation period:<BR/>(1) paracetamol 600 mg plus codeine 60 mg (n = 27)<BR/>(2) placebo (n = 26)<BR/>(3) ketorolac tromethamine 10 mg (n = 22)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-28 08:41:28 +0000" MODIFIED_BY="[Empty name]">
<P>Four-point PI scale (0-3)<BR/>Five-point PR scale (0-4)</P>
<P>Time to remedication</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 2, W = 1. Total = 4/5</P>
<P>Funding: Syntex Research, Palo Alto, California; National Cancer Institute, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-24 14:41:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2003">
<CHAR_METHODS MODIFIED="2013-12-13 14:59:26 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, three-way cross-over, variable observation period (until in moderate or severe pain again)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-24 14:41:51 +0000" MODIFIED_BY="[Empty name]">
<P>18 participants (5 women, 13 men; mean age: 54 years) with moderate or severe cancer pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-13 15:00:28 +0000" MODIFIED_BY="[Empty name]">
<P>(1) codeine 30 mg<BR/>(2) placebo<BR/>(3) codeine 13 mg plus ibuprofen 200 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 15:01:17 +0000" MODIFIED_BY="[Empty name]">
<P>VAS (probably 'visual analogue scale')<BR/>VRS (probably 'verbal rating scale')</P>
<P>Time to effect</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-03 14:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>Oxford Quality Score: R = 1, DB = 2, W = 1. Total = 4/5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Dhaliwal-1995">
<CHAR_METHODS MODIFIED="2014-02-12 10:18:02 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, two-way cross-over, multiple doses, 7-day treatment phases</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-28 15:41:00 +0000" MODIFIED_BY="[Empty name]">
<P>35 participants (30 completers: 13 women, 17 men; mean age: 64 years) with chronic cancer pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-12 10:09:21 +0000" MODIFIED_BY="[Empty name]">
<P>(1) controlled-release codeine at 100, 150 or 200 mg every 2 hours<BR/>(2) placebo<BR/>
<BR/>Rescue medication: paracetamol 300 mg plus codeine 30 mg once or twice every 4 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-23 09:33:20 +0000" MODIFIED_BY="[Empty name]">
<P>100 mm VAS for PI<BR/>Five-point PI scale (0-4)</P>
<P>Doses of rescue medication per day</P>
<P>Pain disability index</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 2, W = 1. Total = 4/5</P>
<P>Funding: Purdue Frederick, Pickering, Ontario</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Jochimsen-1978-I">
<CHAR_METHODS MODIFIED="2013-12-02 13:43:45 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, five-way cross-over, single dose, 6-hour observation periods</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-24 14:43:45 +0000" MODIFIED_BY="[Empty name]">
<P>37 participants (35 completers: 29 women, 6 men; mean age: 57 years) suffering from pain related to malignancies (e.g. breast and gynaecologic malignancies)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 13:43:57 +0000" MODIFIED_BY="[Empty name]">
<P>(1) codeine 60 mg<BR/>(2) codeine 120 mg<BR/>(3) placebo<BR/>(4) benzopyranoperidine 2 mg<BR/>(5) benzopyranoperidine 4 mg<BR/>
<BR/>Rescue with "known analgesic"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-23 09:33:37 +0000" MODIFIED_BY="[Empty name]">
<P>100 mm VAS for PI<BR/>Five-point PR scale (0-4)<BR/>Four-point PI scale<BR/>(PI and PR may have been observer-rated; wording in the paper is ambiguous)</P>
<P>Number of participants receiving rescue medication</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 2, W = 1. Total = 4/5</P>
<P>Funding: National Institutes of Health, USA; Abbott Laboratories</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-22 16:14:02 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Moertel-1971">
<CHAR_METHODS MODIFIED="2013-12-02 13:48:29 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, three-way cross-over, single dose, observation period at least 6 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 13:48:20 +0000" MODIFIED_BY="[Empty name]">
<P>34 participants with unresectable carcinoma with significant pain due to the malignant disease (13 with pancreatic cancer, 21 with colon cancer; age and sex not specified)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 15:04:40 +0100" MODIFIED_BY="[Empty name]">
<P>(1) codeine sulphate 60 mg<BR/>(2) placebo<BR/>(3) aspirin 650 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-22 16:14:02 +0100" MODIFIED_BY="Heather Maxwell">
<P>"percentage scale" for PR of 0%-100%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 2, W = 0. Total = 3/5</P>
<P>Funding: National Institutes of Health, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Noyes-1975">
<CHAR_METHODS MODIFIED="2014-02-12 11:08:05 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, five-way cross-over, single dose, 7-hour observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-25 14:02:17 +0100" MODIFIED_BY="[Empty name]">
<P>36 participants (26 women, 10 men; mean age 51 years) with moderate pain from advanced cancer (13 with breast cancer, 7 with non-Hodgkin's lymphoma, 3 with Hodgkin's disease, 2 each with lung cancer, colon cancer, prostate cancer and malignant melanoma, 1 each with cervix carcinoma, carcinoid, leiomyosarcoma, carcinoma of the parotid gland and anaplastic carcinoma of unknown origin); 34 completers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 13:51:00 +0000" MODIFIED_BY="[Empty name]">
<P>(1) codeine 60 mg<BR/>(2) codeine 120 mg<BR/>(3) placebo<BR/>(4) THC 10 mg<BR/>(5) THC 20 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-23 09:34:07 +0000" MODIFIED_BY="[Empty name]">
<P>Four-point PI scale (0-3)<BR/>Five-point PR scale (0-4)</P>
<P>Sum of pain reduction scores were calculated as pain reduction over 7 hours (maximum possible score estimated as 14)</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 2, W = 1. Total = 4/5</P>
<P>Funding: National Institutes of Health, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Rico-2000">
<CHAR_METHODS MODIFIED="2014-02-12 12:59:04 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, two-way cross-over; 7-day treatment periods with 3-day washout</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-12 13:06:35 +0000" MODIFIED_BY="[Empty name]">
<P>44 participants with oncologic pain (30 women, 14 men: 55 years; baseline pain &gt; 6/10)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-13 10:05:08 +0000" MODIFIED_BY="[Empty name]">
<P>(1) codeine 120 mg daily to max 320 mg daily (average max dose 49 ± 15 mg x 4 daily)</P>
<P>(2) tramadol 160 mg daily to max 400 mg daily (average max dose 68 ± 24 mg x 4 daily)</P>
<P>All participants also received paracetamol 500 mg x 4 daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-23 09:28:04 +0000" MODIFIED_BY="[Empty name]">
<P>10 cm VAS for PI</P>
<P>Patient preference</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 1, W = 1. Total = 3/5</P>
<P>Funding: not specifically reported. Codeine supplied by Yid Mac Farlan Smith Ltd, UK, and tramadol by Grunenthal Laboratories.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Rodriguez-2007">
<CHAR_METHODS MODIFIED="2014-04-09 14:27:42 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, parallel group; 2 day run in, then 21-day treatment period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-13 07:45:36 +0000" MODIFIED_BY="[Empty name]">
<P>177 participants (89 women, 88 men, mean age: 60 years) with persistent moderate or severe cancer pain (primarily gastric, breast, prostate, lung)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-23 09:28:41 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Codeine + paracetamol 150 mg + 2500 mg daily, n = 59</P>
<P>(2) Hydrocodone + paracetamol 25 mg + 2500 mg daily, n = 62</P>
<P>(3) Tramadol 200 mg daily, n = 56</P>
<P>If no PR (VAS &#8805; 4/10) dose could be doubled. If this caused intolerable adverse events it could be reduced by 25%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-23 09:28:51 +0000" MODIFIED_BY="[Empty name]">
<P>10 cm VAS for pain intensity</P>
<P>Five-point PR scale (0-4)</P>
<P>Adverse events</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 2, DB = 2, W = 1. Total = 5/5</P>
<P>Funding: Universidad Libre Seccional Cali, Cali, Colombia; drugs supplied free of charge by Laboratorios Librapharma Ltda., Bogota, D.C., Colombia and Sanofi Synthelabo de Colombia S.A., Cali, Colombia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Stambaugh-1987">
<CHAR_METHODS MODIFIED="2013-12-02 13:53:19 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, four-way cross-over, single dose, 6-hour observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-24 14:48:02 +0000" MODIFIED_BY="[Empty name]">
<P>43 participants (24 women and 10 men (figure given in paper, should probably be: 19 men; mean age: 62 years) with moderate to severe pain due to primary or metastatic malignancy; 40 completers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 13:53:28 +0000" MODIFIED_BY="[Empty name]">
<P>(1) codeine 60 mg<BR/>(2) placebo<BR/>(3) ciramadol 30 mg<BR/>(4) ciramadol 90 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-23 09:29:31 +0000" MODIFIED_BY="[Empty name]">
<P>100 mm VAS for PI<BR/>Four-point PI scale (0-3)<BR/>Six-point PR scale (-1 to +4)</P>
<P>Number of participants remedicating</P>
<P>Number of participants with any adverse event</P>
<P>Withdrawals</P>
<P>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 1, W = 1. Total = 3/5</P>
<P>Funding: Wyeth Laboratories, Philadelphia, Pennsylvania</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Staquet-1971">
<CHAR_METHODS MODIFIED="2014-02-12 14:02:41 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, three-way cross-over, repeated three times in all. Single dose with 6-hour observation period. Minimum 24 hours between study medication and no analgesics within 3 hours of administration</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-12 13:55:28 +0000" MODIFIED_BY="[Empty name]">
<P>Study 1: 18 participants with severe pathologic pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-12 14:38:17 +0000" MODIFIED_BY="[Empty name]">
<P>(1) codeine 30 mg </P>
<P>(2) alclofenac 500 mg</P>
<P>(3) placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-23 09:29:52 +0000" MODIFIED_BY="[Empty name]">
<P>Four point PI scale (0-3)</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 2, DB = 2, W = 1. Total = 3/5</P>
<P>Funding: not reported; first author was working for Continental Pharma, Brussels, Belgium</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Staquet-1978">
<CHAR_METHODS MODIFIED="2013-12-02 13:56:33 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, three-way cross-over, single dose, 6-hour observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 13:56:24 +0000" MODIFIED_BY="[Empty name]">
<P>30 participants with advanced cancer with continuous moderate to severe pain (sex not specified, age range 21-75, no mean age given); 26 completers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-02 13:57:13 +0000" MODIFIED_BY="[Empty name]">
<P>(1) codeine 50 mg<BR/>(2) placebo<BR/>(3) NIB 4 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-23 09:30:10 +0000" MODIFIED_BY="[Empty name]">
<P>Four-point PI scale (0-3)</P>
<P>Withdrawals</P>
<P>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 2, W = 1. Total = 4/5</P>
<P>Funding: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Staquet-1993">
<CHAR_METHODS MODIFIED="2014-02-12 14:22:52 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, parallel group. Single dose with 6-hour observation period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-12 14:26:09 +0000" MODIFIED_BY="[Empty name]">
<P>90 participants (30 women, 58 men analysed; 64 years) with chronic pain due to cancer. Moderate to severe pain 3 or more hours after last analgesic medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-12 14:33:00 +0000" MODIFIED_BY="[Empty name]">
<P>Codeine 60 mg, n = 30</P>
<P>Piroxicam 40 mg, n = 30 (29 analysed)</P>
<P>Codeine 30 mg + piroxicam 20 mg, n = 30 (29 analysed)</P>
<P>Rescue medication available at any time</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-28 08:42:05 +0000" MODIFIED_BY="[Empty name]">
<P>Four-point PI scale (0-3)</P>
<P>Patient global impression of efficacy (poor, fair, good, excellent)</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-27 13:50:16 +0100" MODIFIED_BY="Anna Hobson">
<P>Oxford Quality Score: R = 1, DB = 1, W = 1. Total = 3/5</P>
<P>Funding: Pfizer Belgium</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DB: double-blinding</P>
<P>IM: intramuscular</P>
<P>N: number of participants in trial</P>
<P>n: number of participants in treatment arm</P>
<P>NIB: a synthetic nitrogen analogue of tetrahydrocannabinol</P>
<P>PI: pain intensity</P>
<P>PR: pain relief</P>
<P>R: randomisation</P>
<P>RCT: randomised controlled trial</P>
<P>THC: delta-9-tetrahydrocannabinol</P>
<P>VAS: visual analogue scale</P>
<P>W: withdrawals</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-03-26 17:33:33 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-02-10 11:50:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chary-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-10 11:50:15 +0000" MODIFIED_BY="[Empty name]">
<P>Fewer than 10 participants per treatment arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-26 17:33:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corgill-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-26 17:33:33 +0000" MODIFIED_BY="[Empty name]">
<P>Only a minority of participants had cancer pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-12 19:35:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Conno-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-12 19:35:53 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised, not double-blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-21 15:01:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jochimsen-1978-II">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-21 15:01:37 +0000" MODIFIED_BY="[Empty name]">
<P>Study not stated to be randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-26 17:33:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kantor-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-26 17:33:33 +0000" MODIFIED_BY="[Empty name]">
<P>Most participants had postoperative, postprocedural, or fracture pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-26 17:33:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinetti-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-26 17:33:33 +0000" MODIFIED_BY="[Empty name]">
<P>Only a minority of patients had cancer pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-10 12:27:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Minotti-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-10 12:27:20 +0000" MODIFIED_BY="[Empty name]">
<P>Not investigating codeine alone or with paracetamol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-21 15:06:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Minotti-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-21 15:06:38 +0000" MODIFIED_BY="[Empty name]">
<P>Investigates codeine plus diclofenac versus placebo plus diclofenac</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-10 12:26:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mystakidou-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-10 12:26:02 +0000" MODIFIED_BY="[Empty name]">
<P>Not double-blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-10 12:26:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pistevou_x002d_Gompaki-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-10 12:26:15 +0000" MODIFIED_BY="[Empty name]">
<P>Not double-blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-10 12:27:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sniezek--2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-10 12:27:36 +0000" MODIFIED_BY="[Empty name]">
<P>Investigates postoperative pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-21 15:11:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stambaugh-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-21 15:11:31 +0000" MODIFIED_BY="[Empty name]">
<P>No codeine group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-10 12:27:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sunshine-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-10 12:27:58 +0000" MODIFIED_BY="[Empty name]">
<P>Did not evaluate codeine in cancer pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-10 12:28:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watanabe-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-10 12:28:12 +0000" MODIFIED_BY="[Empty name]">
<P>No codeine used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-07-22 16:09:01 +0100" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-03-20 14:15:58 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:10:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beaver-1978-I">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:10:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beaver-1978-II">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 14:15:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Capretti-1970">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:12:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlson-1990">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:13:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:18:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dhaliwal-1995">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:19:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jochimsen-1978-I">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:07:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moertel-1971">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:08:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noyes-1975">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 15:07:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rico-2000">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-10 12:51:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodriguez-2007">
<DESCRIPTION>
<P>"computer-generated schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:45:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stambaugh-1987">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:22:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staquet-1971">
<DESCRIPTION>
<P>"accomplished by selecting Latin squares at random (with a table of random numbers)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:47:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staquet-1978">
<DESCRIPTION>
<P>Method used to generate sequence not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 14:26:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staquet-1993">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-03-20 14:15:19 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:10:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beaver-1978-I">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:10:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beaver-1978-II">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 14:15:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Capretti-1970">
<DESCRIPTION>
<P>Pre-numbered, coded serial identical containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:12:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlson-1990">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:18:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dhaliwal-1995">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:19:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jochimsen-1978-I">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:07:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moertel-1971">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:08:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noyes-1975">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 15:08:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rico-2000">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 14:34:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2007">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:46:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stambaugh-1987">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 14:04:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staquet-1971">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:47:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staquet-1978">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 14:32:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staquet-1993">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-07-22 16:09:01 +0100" MODIFIED_BY="Heather Maxwell" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-07-22 16:09:01 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Beaver-1978-I">
<DESCRIPTION>
<P>Different doses in capsules and injections were "physically indistinguishable". Double-dummy method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 10:10:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beaver-1978-II">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-20 14:10:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Capretti-1970">
<DESCRIPTION>
<P>Identical packs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 10:13:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carlson-1990">
<DESCRIPTION>
<P>"identical-appearing capsules"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 10:14:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>Double dummy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 10:09:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dhaliwal-1995">
<DESCRIPTION>
<P>"matching placebos"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 10:20:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jochimsen-1978-I">
<DESCRIPTION>
<P>"identical-appearing capsules"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 11:07:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moertel-1971">
<DESCRIPTION>
<P>"Each drug was prepared in a pair of identical opaque blue capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 11:08:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Noyes-1975">
<DESCRIPTION>
<P>"identical in appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-13 10:05:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rico-2000">
<DESCRIPTION>
<P>Method not clearly stated, used the same number of drops and both had bitter taste</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 11:09:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodriguez-2007">
<DESCRIPTION>
<P>"study drugs had similar characteristics such as color, shape, and dimensions and were packaged in identical containers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 11:46:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stambaugh-1987">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 14:06:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staquet-1971">
<DESCRIPTION>
<P>"identical capsules containing the same volume of powder"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 11:47:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staquet-1978">
<DESCRIPTION>
<P>"identical capsules"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-02-12 14:32:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staquet-1993">
<DESCRIPTION>
<P>Method not clearly stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-11-22 13:23:23 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-02-12 12:57:03 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-03-28 08:30:11 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-12 10:10:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beaver-1978-I">
<DESCRIPTION>
<P>Completer analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-12 10:04:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beaver-1978-II">
<DESCRIPTION>
<P>Completer analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-28 08:30:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Capretti-1970">
<DESCRIPTION>
<P>Results for all participants for efficacy, but only 55% for adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-26 13:20:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carlson-1990">
<DESCRIPTION>
<P>Last observation carried forward analysis. Withdrawals &gt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-26 13:20:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>No withdrawals </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-18 16:13:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dhaliwal-1995">
<DESCRIPTION>
<P>Completer analysis. Withdrawals &gt; 10%. Imputation for missing data not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-18 16:18:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jochimsen-1978-I">
<DESCRIPTION>
<P>Withdrawals &lt; 10%. Completer analysis reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-18 16:35:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moertel-1971">
<DESCRIPTION>
<P>Responder analysis appears to include all participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-18 16:38:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Noyes-1975">
<DESCRIPTION>
<P>Withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-24 15:03:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rico-2000">
<DESCRIPTION>
<P>Completer analysis reported. Imputation not mentioned. Withdrawals &gt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-26 13:27:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2007">
<DESCRIPTION>
<P>Imputation not mentioned. Withdrawals not reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-18 16:43:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stambaugh-1987">
<DESCRIPTION>
<P>Withdrawals &lt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-12 14:06:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staquet-1971">
<DESCRIPTION>
<P>Baseline observation carried forward for lack of efficacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-18 16:47:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Staquet-1978">
<DESCRIPTION>
<P>Completer analysis. Pain intensity difference assigned 0 for missing data points</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-19 09:02:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staquet-1993">
<DESCRIPTION>
<P>Baseline observation carried forward imputation for lack of efficacy withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-11-22 13:23:23 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-02-12 12:57:03 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2014-03-20 14:13:02 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Size</NAME>
<DESCRIPTION>
<P>Low risk: &#8805; 200 participants per treatment group</P>
<P>Unclear risk: 50 to 199 participants per treatment group</P>
<P>High risk: &lt; 50 participants per treatment group</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:11:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beaver-1978-I">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n &#8804; 38</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:11:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beaver-1978-II">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n &#8804; 27</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 14:13:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Capretti-1970">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n &#8804; 18</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:13:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carlson-1990">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n &#8804; 27</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:14:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chen-2003">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n = 18</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 10:19:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dhaliwal-1995">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n = 35</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 16:18:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jochimsen-1978-I">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n &#8804; 37</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:07:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moertel-1971">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n = 34</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:09:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Noyes-1975">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n = 36</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 15:11:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rico-2000">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n &#8804; 44</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:09:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-2007">
<DESCRIPTION>
<P>50-200 participants per treatment arm (n &#8804; 62)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:47:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stambaugh-1987">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n = 43</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 14:07:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Staquet-1971">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n = 18</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 11:48:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Staquet-1978">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n = 30</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-12 19:46:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Staquet-1993">
<DESCRIPTION>
<P>&lt; 50 participants per treatment arm: n &#8804; 30</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-07-22 16:19:02 +0100" MODIFIED_BY="Heather Maxwell">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-07-22 16:19:02 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE MODIFIED="2014-03-05 08:31:28 +0000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Codeine ± paracetamol compared with placebo for cancer pain</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>Adults with cancer pain</P>
<P>
<B>Settings: </B>any</P>
<P>
<B>Intervention: </B>codeine 60 mg ± paracetamol single dose</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Outcomes</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Outcome with comparator (placebo)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Outcome with intervention (active)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Relative effect</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Comments</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>At least 50% reduction in pain or equivalent</P>
</TD>
<TD ALIGN="CENTER">
<P>22/69 (32%)</P>
</TD>
<TD ALIGN="CENTER">
<P>39/69 (57%)</P>
</TD>
<TD>
<P>Not calculated</P>
</TD>
<TD>
<P>2 studies, 69 participants</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P>Small numbers of studies and participants. Single dose, cross-over studies.</P>
</TD>
</TR>
<TR>
<TD>
<P>"Moderate" benefit</P>
<P>At least 30% reduction in pain</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>No data</P>
</TD>
<TD>
<P>Not calculated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Proportion below 30/100 mm on VAS</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>No data</P>
</TD>
<TD>
<P>Not calculated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Patient Global Impression of Change much or very much improved</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>No data</P>
</TD>
<TD>
<P>Not calculated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adverse event withdrawals</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>No usable data. Uncommon, 2 reported in one study, unclear during which treatment period</P>
</TD>
<TD>
<P>Not calculated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Serious adverse events</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>None reported, only 1 study specified no serious adverse events</P>
</TD>
<TD>
<P>Not calculated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Death</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2">
<P>3 deaths, all reported to be due to disease progression in the studies</P>
</TD>
<TD>
<P>Not calculated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>VAS: visual analogue scale</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-12-02 15:10:43 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2014-07-23 15:03:43 +0100" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-03-20 17:38:25 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwMAAAKSCAYAAACObwdxAABeoklEQVR42uzdf4RVa/8//puRjJER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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-07-23 15:03:35 +0100" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADOCAMAAADbsfL2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-07-23 15:03:43 +0100" MODIFIED_BY="Heather Maxwell" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAREAAALcCAIAAABPaBMuAAAguklEQVR42u3dv44dx7HH8QUMXDjY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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-07-25 10:13:09 +0100" MODIFIED_BY="Heather Maxwell">
<APPENDIX ID="APP-01" MODIFIED="2014-03-05 14:43:05 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-03-27 13:17:26 +0000" MODIFIED_BY="[Empty name]">MEDLINE (PubMed) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-03-05 14:43:05 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>"Codeine"[mesh] (5254)</LI>
<LI>(codeine or ardinex or isocodeine or n-methylmorphine or &#8220;n methylmorphine&#8221;) (7004)</LI>
<LI>#1 OR #2 (7004)</LI>
<LI>"Neoplasms"[mesh] (2511639)</LI>
<LI>neoplasm* OR cancer* OR carcino* OR malignan* (2809398)</LI>
<LI>tumor* OR tumour* (1298909)</LI>
<LI>#4 OR #5 OR #6 (3403037)</LI>
<LI>"Pain"[mesh] (298062)</LI>
<LI>pain* (542103)</LI>
<LI>"Analgesia"[mesh] (31310)</LI>
<LI>analgesi* (486167)</LI>
<LI>"Analgesics, Opioid"[mesh] (27381)</LI>
<LI>#8 OR #9 OR #10 OR #11 OR #12 (1014939)</LI>
<LI>#3 AND #7 AND #13 (519)</LI>
<LI>randomized controlled trial [pt] (360620)</LI>
<LI>controlled clinical trial [pt] (86996)</LI>
<LI>randomized [tiab] (309269)</LI>
<LI>placebo [tiab] (155403)</LI>
<LI>clinical trials as topic [mesh: noexp] (166483)</LI>
<LI>randomly [tiab] (210255)</LI>
<LI>trial [ti] (123291)</LI>
<LI>#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 (792250)</LI>
<LI>animals [mh] NOT humans [mh] (3864756)</LI>
<LI>#22 NOT #23 (735962)</LI>
<LI>#14 AND #24 (112)</LI>
</OL>
<P>We used the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision); PubMed format (search items 15 to 24).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-03-05 15:19:59 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-11-22 13:02:00 +0000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-03-05 15:19:59 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>MeSH descriptor: [Codeine] explode all trees (972)</LI>
<LI>codeine or ardinex or isocodeine or n-methylmorphine or "n methylmorphine":ti,ab (1273)</LI>
<LI>#1 or #2 (1667)</LI>
<LI>MeSH descriptor: [Neoplasms] explode all trees (49382)</LI>
<LI>neoplasm* or cancer* or carcino* or malignan*:ti,ab (88355)</LI>
<LI>tumor* or tumour*:ti,ab (23427)</LI>
<LI>#4 or #5 or #6 (97219)</LI>
<LI>MeSH descriptor: [Pain] explode all trees (31409)</LI>
<LI>pain*:ti,ab (56963)</LI>
<LI>MeSH descriptor: [Analgesia] explode all trees (5931)</LI>
<LI>analgesi*:ti,ab (22772)</LI>
<LI>MeSH descriptor: [Analgesics, Opioid] explode all trees (5063)</LI>
<LI>#8 or #9 or #10 or #11 or #12 (74334)</LI>
<LI>#3 and #7 and #13 (179)</LI>
<LI>Limit #14 to Trials (105)</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-03-05 15:02:06 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-11-22 13:06:40 +0000" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-03-05 15:02:06 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>codeine/ (17226)</LI>
<LI>(codeine or ardinex or isocodeine or n-methylmorphine or n methylmorphine).mp. (19242)</LI>
<LI>1 or 2 (19242)</LI>
<LI>neoplasm/ (276541)</LI>
<LI>(neoplasm* or cancer* or carcino* or malignan*).mp. (2934038)</LI>
<LI>(tumor* or tumour*).mp. (2260507)</LI>
<LI>4 or 5 or 6 (3699513)</LI>
<LI>exp pain/ (806664)</LI>
<LI>pain*.mp. (836624)</LI>
<LI>analgesia/ (74333)</LI>
<LI>analgesi*.mp. (217344)</LI>
<LI>8 or 9 or 10 or 11 (1148734)</LI>
<LI>clinical trials/ (896014)</LI>
<LI>controlled clinical trials/ (408807)</LI>
<LI>randomized controlled trial/ (367669)</LI>
<LI>random*.ab. (865433)</LI>
<LI>(clin* adj25 trial*).ab. (314441)</LI>
<LI>14 or 15 or 16 or 17 or 18 (1654484)</LI>
<LI>3 and 7 and 12 and 18 (469)</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-07-23 16:22:29 +0100" MODIFIED_BY="Heather Maxwell" NO="4">
<TITLE MODIFIED="2013-12-02 15:07:11 +0000" MODIFIED_BY="[Empty name]">Summary of outcomes in individual studies: efficacy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-23 16:22:29 +0100" MODIFIED_BY="Heather Maxwell">
<TABLE COLS="9" ROWS="16">
<TR>
<TH VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Description of the pharmacological intervention</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Participants with at least 50% reduction in pain</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Participants with VAS pain intensity below 30/100 mm</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Treatment group average pain intensity or pain relief </B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Other measures of pain intensity or pain relief</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Remedication/rescue medication</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Patient global impression of change (participants who are much or very much improved)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Functioning (any scale)</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Beaver-1978-I" TYPE="STUDY">Beaver 1978 I</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Series 1</P>
<P>(1) codeine 30 mg IM</P>
<P>(2) codeine 60 mg IM</P>
<P>(3) codeine 60 mg oral</P>
<P>(4) codeine 120 mg oral</P>
<P>Series 2</P>
<P>(1) codeine 60 mg IM</P>
<P>(2) codeine 180 mg IM</P>
<P>(3) codeine 120 mg oral</P>
<P>(4) codeine 360 mg oral</P>
<P/>
<P>Single dose treatments, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Pain relief at 1 h</P>
<P>Series 1</P>
<P>(1) 1.7</P>
<P>(2) 2.2</P>
<P>(3) 1.7</P>
<P>(4) 1.8</P>
<P>Series 2</P>
<P>(1) 2.1</P>
<P>(2) 2.7</P>
<P>(3) 1.7</P>
<P>(4) 2.4</P>
</TD>
<TD VALIGN="TOP">
<P>Relative potency of oral to IM codeine:</P>
<P>Total analgesic effect 0.6</P>
<P>Peak analgesic effect 0.5</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Beaver-1978-II" TYPE="STUDY">Beaver 1978 II</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Series 1</P>
<P>(1) codeine 90 mg IM</P>
<P>(2) codeine 180 mg IM</P>
<P>(3) oxycodone 7.5 mg IM</P>
<P>(4) oxycodone 15 mg IM</P>
<P>(5) morphine 16 mg IM</P>
<P>Series 2</P>
<P>(1) codeine 90 mg IM</P>
<P>(2) codeine 180 mg IM</P>
<P>(3) oxycodone 15 mg IM</P>
<P>(4) oxycodone 30 mg IM</P>
<P>(5) morphine 16 mg IM</P>
<P/>
<P>Single dose treatments, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Pain relief at 1 h</P>
<P>Series 1</P>
<P>(1) 1.9</P>
<P>(2) 2.6</P>
<P>(3) 2.6</P>
<P>(4) 2.1</P>
<P>(5) 2.6</P>
<P>Series 2</P>
<P>(1) 1.9</P>
<P>(2) 2.6</P>
<P>(3) 2.2</P>
<P>(4) 3.0</P>
<P>(5) 2.3</P>
</TD>
<TD VALIGN="TOP">
<P>Relative potency of IM codeine to IM oxycodone:</P>
<P>Total analgesic effect 0.1</P>
<P>Peak analgesic effect 0.08</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 30 mg</P>
<P>(2) codeine 60 mg</P>
<P>(3) Z 424 50 mg</P>
<P>(4) Z 424 100 mg</P>
<P>(5) placebo</P>
<P/>
<P>1-day treatment, with 4 doses</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Pain relief at end of treatment</P>
<P>(1) 1.28</P>
<P>(2) 1.28</P>
<P>(3) 1.22</P>
<P>(4) 1.22</P>
<P>(5) 0.61</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) paracetamol 600 mg plus codeine 60 mg<BR/>(2) placebo<BR/>(3) ketorolac tromethamine 10 mg</P>
<P/>
<P>7-day treatment period with additional data from first dose, parallel groups</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>3-h SPID<BR/>(1) 1.8<BR/>(2) 0.5</P>
<P>(3) 2.2<BR/>
<BR/>3-h TOTPAR<BR/>(1) 4.0<BR/>(2) 1.9</P>
<P>(3) 4.3<BR/>
<BR/>6-h SPID<BR/>(1) 4.0<BR/>(2) 1.6</P>
<P>(3) 4.6<BR/>
<BR/>6-h TOTPAR<BR/>(1) 9.3<BR/>(2) 4.8</P>
<P>(3) 9.2<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>7-day period:</P>
<P/>
<P>Mean daily pain relief &lt; 3 (a lot) for both treatment groups at all times</P>
</TD>
<TD VALIGN="TOP">
<P>Median time to remedication<BR/>(1) 4.8 h<BR/>(2) 4.0 h</P>
<P>(3) 6.0 h<BR/>significant difference</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 30 mg<BR/>(2) placebo<BR/>(3) codeine 13 mg plus ibuprofen 200 mg</P>
<P/>
<P>Single-dose treatment, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Complete relief (no pain at all)<BR/>(1) 1/18<BR/>(2) 0/18</P>
<P>(3) 2/18<BR/>
<BR/>Partial relief (pain reduced to mild)<BR/>(1) 17/18<BR/>(2) 11/18</P>
<P>(3) 15/18<BR/>
<BR/>Partial or complete pain relief<BR/>(1) 18/18<BR/>(2) 11/18</P>
<P>(3) 17/18<BR/>
<BR/>'Time of showing effect' (min)<BR/>(1) 60 ± 35<BR/>(2) 55 ± 18</P>
<P>(3) 48 ± 19<BR/>
<BR/>'Time of showing the best effect' (min)<BR/>(1) 124 ± 83<BR/>(2) 104 ± 44</P>
<P>(3) 104 ±43<BR/>
<BR/>'Maintaining time' (h)<BR/>(1) 5.4 ± 3.0<BR/>(2) 3.3 ± 2.5</P>
<P>(3) 6.8 ± 4.3<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) controlled-release codeine at 100, 150 or 200 mg every 2 hours<BR/>(2) placebo</P>
<P/>
<P>7-day treatment phases, cross-over<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Participants had mild to moderate pain at baseline</P>
<P/>
<P>Overall mean VAS score<BR/>(1) 22 ± 18<BR/>(2) 36 ± 20<BR/>
<BR/>Overall mean categorical PI score<BR/>(1) 1.2 ± 0.8<BR/>(2) 1.8 ± 0.8<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Rescue medication: doses per day (overall)<BR/>(1) 2.2 ± 2.3<BR/>(2) 4.6 ± 2.8<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Pain disability index (overall, range 0-70)<BR/>(1) 25 ± 16<BR/>(2) 27 ± 16<BR/>
<BR/>Sub-scores for recreation and self-care were better with codeine</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 60 mg<BR/>(2) codeine 120 mg<BR/>(3) placebo<BR/>(4) benzopyranoperidine 2 mg<BR/>(5) benzopyranoperidine 4 mg</P>
<P/>
<P>Single dose, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 17/35<BR/>(2) 20/35<BR/>(3) 15/35</P>
<P>(4) 14/35</P>
<P>(5) 8/35</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Maximum pain relief 3 or 4 on a scale of 0-4<BR/>(1) 14/35<BR/>(2) 19/35<BR/>(3) 12/35</P>
<P>(4) 7/35</P>
<P>(5) 9/35<BR/>
<BR/>'Improvement' in PI score<BR/>(1) 25/35<BR/>(2) 31/35<BR/>(3) 25/35</P>
<P>(4) 19/35</P>
<P>(5) 20/35<BR/>
<BR/>Multiple comparison test performed for PI and PR scores per treatment period: participants receiving 120 mg codeine had better responses than after placebo.</P>
</TD>
<TD VALIGN="TOP">
<P>Received rescue medication (after 4 h)<BR/>(1) 11/35<BR/>(2) 7/35<BR/>(3) 12/35</P>
<P>(4) 19/35</P>
<P>(5) 15/35</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine sulphate 60 mg<BR/>(2) placebo<BR/>(3) aspirin 650 mg</P>
<P/>
<P>Single dose, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 12/34<BR/>(2) 7/34</P>
<P>(3) 20/34</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 60 mg<BR/>(2) codeine 120 mg<BR/>(3) placebo<BR/>(4) THC 10 mg<BR/>(5) THC 20 mg</P>
<P/>
<P>Single dose, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Total pain relief (scored hourly during 7-h observation period, mean ± SE)<BR/>(1) 9.4 ± 1.4<BR/>(2) 12 ± 1.6<BR/>(3) 6.8 ± 0.95</P>
<P>(4) 9.8 ± 1.4</P>
<P>(5) 12.9 ± 1.5<BR/>
<BR/>Total pain reduction (scored hourly during observation period, mean ± SE)<BR/>(1) 3.6 ± 0.75<BR/>(2) 4.3 ± 0.78<BR/>(3) 1.9 ± 0.44</P>
<P>(4) 2.9 ± 0.62</P>
<P>(5) 4.7 ± 0.65<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Number of participants with substantial PR (total PR scores of 12 or more)<BR/>(1) 8/34<BR/>(2) 16/34<BR/>(3) 6/34</P>
<P>(4) 13/34</P>
<P>(5) 16/34</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 30 mg + paracetamol 500 mg 6-hourly</P>
<P>(2) tramadol 40 mg + paracetamol 500 mg 6-hourly</P>
<P/>
<P>7-day treatment phases, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>&#8804; mild pain at end of treatment period</P>
<P>Period 1</P>
<P>(1) 11/21</P>
<P>(2) 9/23</P>
<P>Period 2</P>
<P>(1) 9/16</P>
<P>(2) 6/12</P>
</TD>
<TD VALIGN="TOP">
<P>Mean (SD) pain intensity at end of treatment period</P>
<P>Period 1</P>
<P>(1) 3.4 ± 0.5</P>
<P>(2) 4.1 ± 0.5</P>
<P>Period 2</P>
<P>(1) 3.3 ± 0.1</P>
<P>(2) 3.3 ± 0.6</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 150 mg + paracetamol 2500 mg daily</P>
<P>(2) Tramadol 200 mg daily</P>
<P>(3) Hydrocodone 25 mg + paracetamol 2500 mg daily</P>
<P/>
<P>21-day treatment phase, parallel groups</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 41/59</P>
<P>(2) 40/56</P>
<P>(3) 4/62</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 60 mg<BR/>(2) placebo<BR/>(3) ciramadol 30 mg<BR/>(4) ciramadol 90 mg</P>
<P/>
<P>Single dose, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>6-h SPID<BR/>(1) 4.0<BR/>(2) 2.1</P>
<P>(3) 4.5</P>
<P>(4) 5.6<BR/>
<BR/>6-h TOTPAR<BR/>(1) 7.9<BR/>(2) 5.0</P>
<P>(3) 8.2</P>
<P>(4) 11.2<BR/>
<BR/>6-h SPAID<BR/>(1) 116<BR/>(2) 60</P>
<P>(3) 128</P>
<P>(4) 168</P>
</TD>
<TD VALIGN="TOP">
<P>Maximum mean pain relief score approximately 1.6 (scale -1 to +4)</P>
</TD>
<TD VALIGN="TOP">
<P>Remedicating within 6 hours<BR/>(1) 24/40<BR/>(2) 29/40</P>
<P>(3) 24/40</P>
<P>(4) 18/40</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 30 mg</P>
<P>(2) alclofenac 500 mg</P>
<P>(3) placebo</P>
<P/>
<P>Single dose, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>6-h TOTPAR (SE)</P>
<P>(1) 7.3 ± 0.8</P>
<P>(2) 9.7 ± 0.8</P>
<P>(3) 4.6 ±0.6</P>
</TD>
<TD VALIGN="TOP">
<P>Maximum mean pain relief score approximately 1.4 (scale 0 to 4)</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 50 mg<BR/>(2) placebo<BR/>(3) NIB 4 mg</P>
<P/>
<P>Single dose, cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>6-hour SPID<BR/>(1) 4.8 ± 3.2<BR/>(2) 2.2 ± 2.6</P>
<P>(3) 4.7 ± 3.3<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Staquet-1993" TYPE="STUDY">Staquet 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 60 mg</P>
<P>(2) piroxicam 40 mg</P>
<P>(3) codeine 60 mg + piroxicam 40 mg</P>
<P/>
<P>Single dose, parallel groups</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>6-h SPID from graph</P>
<P>(1) 2.7</P>
<P>(2) 2.4</P>
<P>(3) 2.3</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>Mean (SD)</P>
<P>(1) 1.7 ±1.2</P>
<P>(2) 1.5 ± 1.3</P>
<P>(3) 1.7 ± 1.1</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
</TR>
</TABLE>
<P>IM: intramuscular</P>
<P>NIB: a synthetic nitrogen analogue of tetrahydrocannabinol</P>
<P>PI: pain intensity</P>
<P>PR: pain relief</P>
<P>SE: standard error</P>
<P>SPAID: sum of pain analogue intensity differences</P>
<P>SPID: summed pain intensity difference</P>
<P>VAS: visual analogue scale</P>
<P>THC: delta-9-tetrahydrocannabinol</P>
<P>TOTPAR: total pain relief</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-07-25 10:13:09 +0100" MODIFIED_BY="Heather Maxwell" NO="5">
<TITLE MODIFIED="2013-12-02 15:09:11 +0000" MODIFIED_BY="[Empty name]">Summary of outcomes in individual studies: adverse events, withdrawals and deaths</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-25 10:13:09 +0100" MODIFIED_BY="Heather Maxwell">
<TABLE COLS="8" ROWS="16">
<TR>
<TH VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Description of the pharmacological intervention</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Participants with any adverse event</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Participants with any serious adverse event</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Withdrawal (any reason)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Withdrawal (due to adverse events)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Withdrawal (due to lack of efficacy)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Beaver-1978-I" TYPE="STUDY">Beaver 1978 I</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Series 1</P>
<P>(1) codeine 30 mg IM</P>
<P>(2) codeine 60 mg IM</P>
<P>(3) codeine 60 mg oral</P>
<P>(4) codeine 120 mg oral</P>
<P>Series 2</P>
<P>(1) codeine 60 mg IM</P>
<P>(2) codeine 180 mg IM</P>
<P>(3) codeine 120 mg oral</P>
<P>(4) codeine 360 mg oral</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Beaver-1978-II" TYPE="STUDY">Beaver 1978 II</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Series 1</P>
<P>(1) codeine 90 mg IM</P>
<P>(2) codeine 180 mg IM</P>
<P>(3) oxycodone 7.5 mg IM</P>
<P>(4) oxycodone 15 mg IM</P>
<P>(5) morphine 16 mg IM</P>
<P>Series 2</P>
<P>(1) codeine 90 mg IM</P>
<P>(2) codeine 180 mg IM</P>
<P>(3) oxycodone 15 mg IM</P>
<P>(4) oxycodone 30 mg IM</P>
<P>(5) morphine 16 mg IM</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Capretti-1970" TYPE="STUDY">Capretti 1970</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 30 mg</P>
<P>(2) codeine 60 mg</P>
<P>(3) Z 424 50 mg</P>
<P>(4) Z 424 100 mg</P>
<P>(5) placebo</P>
<P/>
<P>1-day treatment, with 4 doses</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Carlson-1990" TYPE="STUDY">Carlson 1990</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 60 mg plus paracetamol 600 mg<BR/>(2) placebo<BR/>(3) ketorolac tromethamine 10 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Multidose phase</P>
<P>(1) 19/40</P>
<P>(3) 21/34</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>Multidose phase</P>
<P>(1) 13/40</P>
<P>(3) 17/34</P>
</TD>
<TD VALIGN="TOP">
<P>Multidose phase</P>
<P>(1) 4/40</P>
<P>(3) 8/34 (3 also had unsatisfactory pain relief)</P>
</TD>
<TD VALIGN="TOP">
<P>Within 6 h ("terminated the 6-h first-dose observation period early because of inadequate pain relief")<BR/>(1) 10/27<BR/>(2) 14/26</P>
<P>(3) 6/22</P>
<P/>
<P>Multidose phase</P>
<P>(1) 7/40</P>
<P>(3) 11/34 (3 also had unsatisfactory pain relief)</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chen-2003" TYPE="STUDY">Chen 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 30 mg<BR/>(2) placebo<BR/>(3) codeine 13 mg plus ibuprofen 200 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>0/18</P>
</TD>
<TD VALIGN="TOP">
<P>0/18</P>
</TD>
<TD VALIGN="TOP">
<P>0/18</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dhaliwal-1995" TYPE="STUDY">Dhaliwal 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) controlled-release codeine at 100, 150 or 200 mg every 2 h<BR/>(2) placebo<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 3/35<BR/>(2) 2/35</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 2/35<BR/>(2) 0/35</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 0/35<BR/>(2) 0/35</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jochimsen-1978-I" TYPE="STUDY">Jochimsen 1978 I</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 60 mg<BR/>(2) codeine 120 mg<BR/>(3) placebo<BR/>(4) benzopyranoperidine 2 mg<BR/>(5) benzopyranoperidine 4 mg<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>2/37<BR/>no more detail given</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Moertel-1971" TYPE="STUDY">Moertel 1971</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine sulfate 60 mg<BR/>(2) placebo<BR/>(3) aspirin 650 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Noyes-1975" TYPE="STUDY">Noyes 1975</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 60 mg<BR/>(2) codeine 120 mg<BR/>(3) placebo<BR/>(4) THC 10 mg<BR/>(5) THC 20 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>2/36</P>
</TD>
<TD VALIGN="TOP">
<P>2/36 due to adverse reaction to THC</P>
</TD>
<TD VALIGN="TOP">
<P>0/36</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rico-2000" TYPE="STUDY">Rico 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 30 mg</P>
<P>(2) tramadol 40 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>First period</P>
<P>(1) 7/21</P>
<P>(2) 9/23</P>
</TD>
<TD VALIGN="TOP">
<P>First period</P>
<P>(1) 3/21</P>
<P>(2) 0/23</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rodriguez-2007" TYPE="STUDY">Rodriguez 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 150 mg + paracetamol 2500 mg daily</P>
<P>(2) Tramadol 200 mg daily</P>
<P>(3) Hydrocodone 25 mg + paracetamol 2500 mg daily</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No adverse event withdrawals for codeine + paracetamol or hydrocodone + paracetamol. No data for tramadol</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Stambaugh-1987" TYPE="STUDY">Stambaugh 1987</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 60 mg<BR/>(2) placebo<BR/>(3) ciramadol 30 mg<BR/>(4) ciramadol 90 mg</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 10/41<BR/>(2) 5/41</P>
<P>(3) 7/40</P>
<P>(4) 10/42</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>3/43<BR/>(including 2 deaths)</P>
</TD>
<TD VALIGN="TOP">
<P>0/43</P>
</TD>
<TD VALIGN="TOP">
<P>0/43</P>
</TD>
<TD VALIGN="TOP">
<P>Two patients died of their disease during the study (no more details given)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Staquet-1971" TYPE="STUDY">Staquet 1971</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 30 mg</P>
<P>(2) alclofenac 500 mg</P>
<P>(3) placebo</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>None: "in all cases symptoms were minimal"</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>None reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Staquet-1978" TYPE="STUDY">Staquet 1978</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 50 mg<BR/>(2) placebo<BR/>(3) NIB 4 mg</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>4/30<BR/>(including 1 death)</P>
</TD>
<TD VALIGN="TOP">
<P>2/30</P>
</TD>
<TD VALIGN="TOP">
<P>0/30</P>
</TD>
<TD VALIGN="TOP">
<P>One death due to terminal cancer</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Staquet-1993" TYPE="STUDY">Staquet 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>(1) codeine 60 mg</P>
<P>(2) piroxicam 40 mg</P>
<P>(3) codeine 60 mg + piroxicam 40 mg</P>
</TD>
<TD VALIGN="TOP">
<P>(1) 5/30</P>
<P>(2) 2/29</P>
<P>(3) 2/30</P>
</TD>
<TD VALIGN="TOP">
<P>No data</P>
</TD>
<TD VALIGN="TOP">
<P>1 participant excluded from efficacy analysis in (2) and 1 in (3) due to missing data</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
<TD VALIGN="TOP">
<P>None</P>
</TD>
</TR>
</TABLE>
<P>IM: intramuscular</P>
<P>NIB: a synthetic nitrogen analogue of tetrahydrocannabinol</P>
<P>THC: delta-9-tetrahydrocannabinol</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-05-02 10:21:08 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-02-27 10:26:32 +0000" MODIFIED_BY="[Empty name]">Specific adverse events in multidose studies</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-02 10:21:08 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="10" ROWS="11">
<TR>
<TH ALIGN="CENTER">
<P>Study ID</P>
</TH>
<TH ALIGN="CENTER">
<P>Drug</P>
</TH>
<TH ALIGN="CENTER">
<P>Nausea</P>
</TH>
<TH ALIGN="CENTER">
<P>Vomiting</P>
</TH>
<TH ALIGN="CENTER">
<P>Constipation</P>
</TH>
<TH ALIGN="CENTER">
<P>Diarrhoea</P>
</TH>
<TH ALIGN="CENTER">
<P>Dyspepsia</P>
</TH>
<TH ALIGN="CENTER">
<P>Anorexia</P>
</TH>
<TH ALIGN="CENTER">
<P>Somnolence</P>
</TH>
<TH ALIGN="CENTER">
<P>Dizziness</P>
</TH>
</TR>
<TR>
<TD>
<P>Capretti 1970</P>
</TD>
<TD>
<P>Codeine</P>
</TD>
<TD ALIGN="CENTER">
<P>1/10</P>
</TD>
<TD ALIGN="CENTER">
<P>4/10</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>3/10</P>
</TD>
<TD ALIGN="CENTER">
<P>1/10 (vertigo)</P>
</TD>
</TR>
<TR>
<TD>
<P>Carlson 1990</P>
</TD>
<TD>
<P>Codeine + paracetamol</P>
</TD>
<TD ALIGN="CENTER">
<P>12/40</P>
</TD>
<TD ALIGN="CENTER">
<P>5/40</P>
</TD>
<TD ALIGN="CENTER">
<P>1/40</P>
</TD>
<TD ALIGN="CENTER">
<P>0/40</P>
</TD>
<TD ALIGN="CENTER">
<P>4/40</P>
</TD>
<TD ALIGN="CENTER">
<P>1/40</P>
</TD>
<TD ALIGN="CENTER">
<P>3/40</P>
</TD>
<TD ALIGN="CENTER">
<P>2/40</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Ketorolac</P>
</TD>
<TD ALIGN="CENTER">
<P>7/34</P>
</TD>
<TD ALIGN="CENTER">
<P>3/34</P>
</TD>
<TD ALIGN="CENTER">
<P>1/40</P>
</TD>
<TD ALIGN="CENTER">
<P>6/34</P>
</TD>
<TD ALIGN="CENTER">
<P>5/34</P>
</TD>
<TD ALIGN="CENTER">
<P>1/34</P>
</TD>
<TD ALIGN="CENTER">
<P>1/34</P>
</TD>
<TD ALIGN="CENTER">
<P>4/34</P>
</TD>
</TR>
<TR>
<TD>
<P>Dhaliwal 1995</P>
</TD>
<TD>
<P>Codeine (controlled-release)</P>
</TD>
<TD ALIGN="CENTER">
<P>14/35</P>
</TD>
<TD ALIGN="CENTER">
<P>5/35</P>
</TD>
<TD ALIGN="CENTER">
<P>11/35</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>5/35</P>
</TD>
<TD ALIGN="CENTER">
<P>5/35</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD ALIGN="CENTER">
<P>5/35</P>
</TD>
<TD ALIGN="CENTER">
<P>2/35</P>
</TD>
<TD ALIGN="CENTER">
<P>12/35</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0/35</P>
</TD>
<TD ALIGN="CENTER">
<P>3/35</P>
</TD>
</TR>
<TR>
<TD>
<P>Rico 2000</P>
</TD>
<TD>
<P>Codeine + paracetamol</P>
</TD>
<TD ALIGN="CENTER">
<P>18/37</P>
</TD>
<TD ALIGN="CENTER">
<P>16/37</P>
</TD>
<TD ALIGN="CENTER">
<P>19/37 (mod/sev)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Tramadol</P>
</TD>
<TD ALIGN="CENTER">
<P>14/35</P>
</TD>
<TD ALIGN="CENTER">
<P>11/35</P>
</TD>
<TD ALIGN="CENTER">
<P>12/35 (mod/sev)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Rodriguez 2007</P>
</TD>
<TD>
<P>Codeine + paracetamol</P>
</TD>
<TD ALIGN="CENTER">
<P>17/59</P>
</TD>
<TD ALIGN="CENTER">
<P>14/59</P>
</TD>
<TD ALIGN="CENTER">
<P>21/59</P>
</TD>
<TD ALIGN="CENTER">
<P>0/59</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>1/59</P>
</TD>
<TD ALIGN="CENTER">
<P>21/59</P>
</TD>
<TD ALIGN="CENTER">
<P>14/59</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Hydrocodone + paracetamol</P>
</TD>
<TD ALIGN="CENTER">
<P>17/62</P>
</TD>
<TD ALIGN="CENTER">
<P>10/62</P>
</TD>
<TD ALIGN="CENTER">
<P>18/62</P>
</TD>
<TD ALIGN="CENTER">
<P>3/62</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>4/62</P>
</TD>
<TD ALIGN="CENTER">
<P>23/62</P>
</TD>
<TD ALIGN="CENTER">
<P>12/62</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Tramadol</P>
</TD>
<TD ALIGN="CENTER">
<P>26/56</P>
</TD>
<TD ALIGN="CENTER">
<P>20/56</P>
</TD>
<TD ALIGN="CENTER">
<P>14/56</P>
</TD>
<TD ALIGN="CENTER">
<P>1/56</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>12/56</P>
</TD>
<TD ALIGN="CENTER">
<P>26/56</P>
</TD>
<TD ALIGN="CENTER">
<P>23/56</P>
</TD>
</TR>
</TABLE>
<P>mod: moderate</P>
<P>sev: severe</P>
<P/>
<TABLE COLS="9" ROWS="11">
<TR>
<TH ALIGN="CENTER">
<P>Study ID</P>
</TH>
<TH ALIGN="CENTER">
<P>Drug</P>
</TH>
<TH ALIGN="CENTER">
<P>Headache</P>
</TH>
<TH ALIGN="CENTER">
<P>Insomnia</P>
</TH>
<TH ALIGN="CENTER">
<P>Dry mouth</P>
</TH>
<TH ALIGN="CENTER">
<P>Asthenia</P>
</TH>
<TH ALIGN="CENTER">
<P>Sweating</P>
</TH>
<TH ALIGN="CENTER">
<P>Pruritus</P>
</TH>
<TH ALIGN="CENTER">
<P>Hallucinations</P>
</TH>
</TR>
<TR>
<TD>
<P>Capretti 1970</P>
</TD>
<TD>
<P>Codeine</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>2/10 (hot sensation)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carlson 1990</P>
</TD>
<TD>
<P>Codeine + paracetamol</P>
</TD>
<TD ALIGN="CENTER">
<P>1/40</P>
</TD>
<TD ALIGN="CENTER">
<P>0/40</P>
</TD>
<TD ALIGN="CENTER">
<P>2/40</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>1/40</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Ketorolac</P>
</TD>
<TD ALIGN="CENTER">
<P>7/34</P>
</TD>
<TD ALIGN="CENTER">
<P>2/34</P>
</TD>
<TD ALIGN="CENTER">
<P>0/34</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0/34</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Dhaliwal 1995</P>
</TD>
<TD>
<P>Codeine (controlled-release)</P>
</TD>
<TD ALIGN="CENTER">
<P>8/35</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>7/35</P>
</TD>
<TD ALIGN="CENTER">
<P>5/35</P>
</TD>
<TD ALIGN="CENTER">
<P>3/35</P>
</TD>
<TD ALIGN="CENTER">
<P>2/35</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD ALIGN="CENTER">
<P>7/35</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>7/35</P>
</TD>
<TD ALIGN="CENTER">
<P>2/35</P>
</TD>
<TD ALIGN="CENTER">
<P>2/35</P>
</TD>
<TD ALIGN="CENTER">
<P>0/35</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Rico 2000</P>
</TD>
<TD>
<P>Codeine + paracetamol</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Tramadol</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Rodriguez 2007</P>
</TD>
<TD>
<P>Codeine + paracetamol</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0/59</P>
</TD>
<TD ALIGN="CENTER">
<P>9/59</P>
</TD>
<TD ALIGN="CENTER">
<P>0/59</P>
</TD>
<TD ALIGN="CENTER">
<P>5/59</P>
</TD>
<TD ALIGN="CENTER">
<P>7/59</P>
</TD>
<TD ALIGN="CENTER">
<P>4/59</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Hydrocodone + paracetamol</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>0/62</P>
</TD>
<TD ALIGN="CENTER">
<P>11/62</P>
</TD>
<TD ALIGN="CENTER">
<P>1/62</P>
</TD>
<TD ALIGN="CENTER">
<P>9/62</P>
</TD>
<TD ALIGN="CENTER">
<P>12/62</P>
</TD>
<TD ALIGN="CENTER">
<P>7/62</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Tramadol</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>2/56</P>
</TD>
<TD ALIGN="CENTER">
<P>12/56</P>
</TD>
<TD ALIGN="CENTER">
<P>7/56</P>
</TD>
<TD ALIGN="CENTER">
<P>7/56</P>
</TD>
<TD ALIGN="CENTER">
<P>11/56</P>
</TD>
<TD ALIGN="CENTER">
<P>4/56</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;No studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;29 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;105 of records identified in CENTRAL&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;112 records identified in MEDLINE&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;469 records identified in EMBASE&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;5 additional records identified through screening reference lists&lt;/p&gt;"/>
<OUT TEXT="&lt;p&gt;14 full-text articles excluded:&lt;/p&gt;&lt;p&gt;Not limited to cancer 5&lt;/p&gt;&lt;p&gt;Not randomised and/or double blind 4&lt;/p&gt;&lt;p&gt;Not codeine &amp;#177; paracetamol 4&lt;/p&gt;&lt;p&gt;&amp;lt; 10 participants 1&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>